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Abstract
Acidity in the tumor microenvironment (TME) is related to invasion, metastasis, and chemotherapeutic
resistance, all of which are contributors to poor prognoses in cancer patients. In this thesis, we propose
the application of Cerenkov radiation as a tool for imaging pH in vivo through the measurement of
Selective Bandwidth Quenching (SBQ) and Cerenkov Radiation Energy Transfer (CRET) in triple negative
human breast cancer models MDA-MB-231 and 4175-Luc+. To test the hypothesis that SBQ and CRET
signals could provide measurements of TME pH in vivo, a Cerenkov-active molecule, NFbD, was
conjugated and chelated with 68Ga. Cerenkov imaging was performed with NFbD-Ga in vitro to construct
pH titration curves, later used to interpolate in vivo Cerenkov pH values. In vivo Cerenkov imaging was
performed on athymic nude mice bearing 4175-Luc+ triple negative breast cancer xenografts after
intratumoral injections of NFbD-Ga (40 μCi). CRET values obtained from in vivo Cerenkov imaging were
used to estimate TME pH values, which were validated by 31P Magnetic Resonance Spectroscopy (31P
MRS) following i.p. injection of 3-APP. Tissue scattering, and absorption effects were evaluated in vitro
with tissue phantoms. NFbD maintained its pH-sensitivity after conjugation (pKa= 7.8, λex= 599 nm,
λem= 669 nm at pH 9). SBQ and CRET were observed in vitro inter-and intramolecularly, at 600 nm and
700 nm, respectively. SBQ and CRET were also observed in vivo. CRET measurements following
intratumoral injections of NFbD-Ga yielded a tumor pHCerenkov= 6.90 ± 0.16, 31P-MRS on the same
tumors yielded a pHMRS= 6.92 ± 0.04. Chicken tissue phantoms provided insight on tissue attenuation
effects, showing that 1 mm of tissue can attenuate 64% of the Cerenkov signal, in the absence of
naphthofluorescein and further attenuation to 17% is achieved with the addition of naphthofluorescein.
The synthesis and development of this Cerenkov-active, pH sensitive probe for the determination of TME
pH provided detectable CRET signals in vivo, allowing Cerenkov to be used as a potential technique for
non-invasive pH imaging.
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ABSTRACT
DEVELOPMENT OF A PH-SENSITIVE PROBE FOR IN VIVO CERENKOV
IMAGING OF THE TUMOR MICROENVIRONMENT
Andrea E. Rodríguez Ríos
E. James Delikatny

Acidity in the tumor microenvironment (TME) is related to invasion, metastasis, and
chemotherapeutic resistance, all of which are contributors to poor prognoses in cancer
patients. In this thesis, we propose the application of Cerenkov radiation as a tool for
imaging pH in vivo through the measurement of Selective Bandwidth Quenching (SBQ)
and Cerenkov Radiation Energy Transfer (CRET) in triple negative human breast cancer
models MDA-MB-231 and 4175-Luc+. To test the hypothesis that SBQ and CRET
signals could provide measurements of TME pH in vivo, a Cerenkov-active molecule,
NFbD, was conjugated and chelated with 68Ga. Cerenkov imaging was performed with
NFbD-Ga in vitro to construct pH titration curves, later used to interpolate in vivo
Cerenkov pH values. In vivo Cerenkov imaging was performed on athymic nude mice
bearing 4175-Luc+ triple negative breast cancer xenografts after intratumoral injections
of NFbD-Ga (40 μCi). CRET values obtained from in vivo Cerenkov imaging were used
to estimate TME pH values, which were validated by 31P Magnetic Resonance
Spectroscopy (31P MRS) following i.p. injection of 3-APP. Tissue scattering, and
absorption effects were evaluated in vitro with tissue phantoms. NFbD maintained its pHsensitivity after conjugation (pKa= 7.8, λex= 599 nm, λem= 669 nm at pH 9). SBQ and
CRET were observed in vitro inter-and intramolecularly, at 600 nm and 700 nm,
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respectively. SBQ and CRET were also observed in vivo. CRET measurements following
intratumoral injections of NFbD-Ga yielded a tumor pHCerenkov= 6.90 ± 0.16, 31P-MRS on
the same tumors yielded a pHMRS= 6.92 ± 0.04. Chicken tissue phantoms provided insight
on tissue attenuation effects, showing that 1 mm of tissue can attenuate 64% of the
Cerenkov signal, in the absence of naphthofluorescein and further attenuation to 17% is
achieved with the addition of naphthofluorescein. The synthesis and development of this
Cerenkov-active, pH sensitive probe for the determination of TME pH provided
detectable CRET signals in vivo, allowing Cerenkov to be used as a potential technique
for non-invasive pH imaging.
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Chapter 1
Introduction

1.1 Breast Cancer
Breast cancer is the most common cancer affecting women. In 2022, the
American Cancer Society estimates that almost 288,000 new cases of invasive breast
cancer will be diagnosed and around 43,000 women will die from this disease (2022a).
Breast cancer is considered curable when it is in situ, contained within the breast tissue or
only spread to axillary lymph nodes. Metastatic breast cancer is treatable, however, it is
considered incurable with currently available therapeutic options (Harbeck et al., 2019).
Treatment of metastatic breast cancer mainly focuses on prolonging survival and
improving quality of life.

Breast cancer is considered a heterogeneous disease and can be classified by the
presence of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth
receptor 2 (HER2) or by the absence of these receptors, as presented in Figure 1.1 (Costa
et al., 2020). When breast cancer is ER, PR and HER2 negative, it is referred to as Triple
Negative Breast Cancer (TNBC), which is aggressive and lacks targeted therapies
(Anders and Carey, 2008). Tissue samples resected from breast cancer patients are tested
for these markers to provide a framework for therapeutics and next steps (Harbeck et al.,
2019). Understanding disease pathology and its molecular mechanism aids in the
development of new and better therapeutics, enhancing patient prognosis.
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Figure 1.1. Molecular classification of breast cancer. Table adapted from (Costa et al., 2020) shows
breast cancer markers used to classify breast cancers clinically. Ki-67 is a proliferation marker.

In vitro and in vivo models of breast cancer have been developed to mimic
the microenvironment and molecular characteristics of this disease. In research studies,
breast cancer cell lines are chosen , according to the aims of the study, to elucidate
specific information based on their metabolic profiles (Kao et al., 2009). The most
common breast cancer cell lines used in research are MCF7 (ER+, PR+), T47D (ER+,
PR+) and MDA-MB-231(TNBC) (Dai et al., 2017), all of which were originally isolated
from patients (2022b; 2022c; 2022f).

MDA-MB-231 is a metastatic TNBC that is used to model late-stage breast
cancer. This cell line grows well in vitro and produces breast cancer tumor xenografts
when implanted in mice (Welsh, 2013). In 2005, Andy Minn et al. developed a metastatic
variant of MDA-MB-231 by injecting MDA-MB-231 cells into the tail vein of
immunodeficient mice, harvesting lung metastases, expanding them in tissue culture and
injecting them again (Minn et al., 2005). This process was repeated several times,
2

followed by transfection with luciferase and GFP to produce the bioluminescent cell line
4175-Luc+. Both MDA-MB-231 and its metastatic variant 4175-Luc+ cell lines are
currently used as in vitro and in vivo breast cancer models in our lab (Arlauckas et al.,
2017; Arroyo et al., 2019).

1.2 Hallmarks of Cancer
Hanahan and Weinberg described the Hallmarks of Cancer in 2000, six
categorized processes that occur in the development of all cancerous tissues, allowing
malignant cells to survive, proliferate and spread (Hanahan and Weinberg, 2000). These
hallmarks include: sustaining proliferative signaling, evading growth suppressors,
activating invasion and metastasis, enabling replicative immortality, inducing
angiogenesis, and resisting cell death (Figure 1.2.A). The Hallmarks of Cancer were
revised in 2011, and four additional hallmarks were included, also called “emerging
hallmarks”, which include: genome instability and mutation, deregulating cellular
energetics, avoiding immune destruction and tumor-promoting inflammation (Hanahan
and Weinberg, 2011), described in Figure 1.2.B. Identifying and conducting research
A

B

Figure 1.2 Hallmarks of Cancer. Adapted from (Hanahan and Weinberg, 2011; Hanahan and
Weinberg, 2000). A. Scheme showing the original Hallmarks of Cancer. B. Scheme including
the original Hallmarks of Cancer and Emerging hallmarks.

3

addressing these processes have aided in the development of novel targeted therapeutics
(Senga and Grose, 2021).
Hanahan and Weinberg correctly predicted the further evolution of the Hallmarks
of Cancer, due to advances in research. In 2021, Sasi Senga and Richard Grose proposed
including four additional hallmarks to the ones already defined. These are as follows:
dedifferentiation and transdifferentiation, epigenetic dysregulation, altered microbiome
and altered neuronal signaling (Senga and Grose, 2021). Some of these new hallmarks
were also addressed by Hanahan himself in his latest publication “Hallmarks of Cancer:
New Dimensions” (Hanahan, 2022). He refers to dedifferentiation and
transdifferentiation as “unlocking phenotypic plasticity”, epigenetic dysregulation is
referred to as “nonmutational epigenetic reprogramming”, and touches on altered
microbiome in terms of “polymorphic microbiomes”. Hanahan includes an additional
hallmark, where he proposes cell senescence as a characteristic that promotes malignant
progression.

1.3 Deregulation of Cellular energetics
The deregulation of cellular energetics was described as an emerging hallmark of
cancer in 2011, and is now considered a core hallmark (Hanahan, 2022). Malignant cells
undergo dysregulated division, which requires altering the way in which these cells
obtain energy to sustain their fast proliferative rates. Cancer cells do this by increasing
their rates of glycolysis, even when there is oxygen available. This phenomenon is called
the Warburg Effect and has been described as aerobic glycolysis (Warburg et al., 1927) .
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Relying on glycolysis for energetic production is not as efficient as oxidative
phosphorylation (OXPHOS). Glycolysis produces 2 molecules of ATP, while OXPHOS
produces up to 36 ATP molecules (Vander Heiden et al., 2009). Cells compensate by
upregulating glucose transporters, such as glucose transporter isoform 1 (GLUT1), to
increase glycolytic rates (Barbosa and Martel, 2020; Ooi and Gomperts, 2015). Increased
glycolytic rates also occur due to hypoxic conditions frequently observed in tumors,
which activates the transcription factor hypoxia-inducible factor (HIF). Activation of HIF
can upregulate GLUT1, hexokinase (HK), lactate dehydrogenase A (LDHA) and
monocarboxylate transporter 4 (MCT4) (Kroemer and Pouyssegur, 2008). As previously
mentioned, GLUT1 is a glucose transporter that aids in glucose transfer into the cytosol,
from the extracellular milieu. Hexokinase catalyzes the first step of glycolysis,
phosphorylating glucose and converting it into glucose-6-phosphate (Mathupala et al.,
2006). LDHA catalyzes the conversion from pyruvate to lactate, in the last step of
glycolysis (Jafary et al., 2019), while MCT4 releases lactate from the cells with a proton
as a counterion (Contreras-Baeza et al., 2019).

Although inefficient, glycolysis with a high enough rate can produce an amount
of ATP that exceeds the amount of ATP produced from oxidative phosphorylation
(DeBerardinis et al., 2008). In addition, glycolysis provides cells with byproducts
required for biosynthesis, such as ribose sugars (nucleotides), glycerol and citrate (lipids),
and NADPH (pentose phosphate pathway), aiding in cell proliferation (DeBerardinis et
al., 2008). It is important to note that oxidative phosphorylation still occurs in cancer
cells. It is possible that the function of the Warburg effect is to allow cells to maintain a
5

steady stream of glycolytic intermediates to be used for biosynthesis (DeBerardinis and
Chandel, 2020). This machinery benefits cancer cells by playing a role in both
bioenergetics and biosynthesis. LDHA and MCT4 upregulation, for example, produce
and excrete lactate, respectively, that will become part of the tumor microenvironment.
Lactate had been previously considered a glycolytic byproduct that is excreted from cells
as waste (Vander Heiden et al., 2009), but emerging evidence has shown that lactate can
be consumed by stromal cells in the tumor microenvironment to regenerate pyruvate as a
source of energy (Pérez-Tomás and Pérez-Guillén, 2020), resulting in a symbiotic
interaction between glycolytic tumor cells and oxidative stromal cells (Rattigan et al.,
2012).

1.4 pH modulation in tumors
Increased glycolytic rates due to the deregulation of cellular energetics result in
increased lactate production. This lactate accumulates in the cytosol and must be excreted
from the cell to prevent intracellular acidification and to maintain the glycolytic gradient
(Pérez-Tomás and Pérez-Guillén, 2020). Lactate secretion occurs through MCTs,
particularly MCT4, which is a H+ coupled symporter (Contreras-Baeza et al., 2019). This
means that lactate excretion occurs with a proton as a counter ion, whose extracellular
accumulation increases acidity in the TME. Cancer cells overexpress other enzymes in
addition to MCTs that are able to transport protons to the extracellular milieu as well,
such as H+-ATPases and the Na+-H+ exchanger NHE1, which also contribute to
acidification (Webb et al., 2011). Conversion of CO2 to H+ and HCO3 by carbonic
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anhydrases, also plays a role in increased extracellular acidity (Pavlova and Thompson,
2016).

Physiological pH is highly controlled and maintained at around pH 7.4, whereas
local pH in the TME ranges from 6.5 to 6.9 (Estrella et al., 2013). This decrease in pH
results in a “reverse pH gradient” in which the extracellular pH is lower than the
intracellular pH in the TME (Webb et al., 2011). Since many cellular processes are
dependent on pH, TME acidification has important implications in cancer progression
and therapeutic options (Pérez-Tomás and Pérez-Guillén, 2020).

Increased acidity of the TME aids in the immune escape of malignant cells and
proteolytic degradation of the extracellular matrix (Pérez-Tomás and Pérez-Guillén,
2020). Acidic TME is able to suppress some immune cells such as cytolytic T cells
(Hashim et al., 2011). In addition, matrix metalloproteinases (MMP) and cathepsins are
examples of enzymes whose function is to degrade the extracellular matrix, facilitating
tumor cell invasion and subsequent cell migration from the tumor to other sites of the
body. These enzymes are activated by a lower pH and their activity fosters invasion and
metastasis (Hashim et al., 2011).

Low pH in the TME is also related to chemotherapeutic resistance through
various mechanisms. Firstly, acidic conditions correlate with increased expression of the
efflux transporter p-glycoprotein, which transports foreign substances out of cells
(Hamaguchi et al., 2020). Inhibition of this transporter has improved efficacy of some
7

chemotherapeutics (Abumanhal-Masarweh et al., 2019; Thews et al., 2006). Second,
decreased pH in the TME can have an “ion trapping” effect on weak base
chemotherapeutics, such as doxorubicin, which become ionized extracellularly and
become cell impermeable, reducing chemotherapeutic efficiency (Gerweck et al., 2006;
Wojtkowiak et al., 2011). Increased acidity can also cause changes to the expression of
target proteins, decreasing therapeutic efficiency (Kolosenko et al., 2017).

1.5 Optical Imaging
Optical imaging is a non-invasive technique in which visible light is detected for
the identification of molecular markers in vivo and in vitro. It mainly refers to light
detection through fluorescence or bioluminescence (Fokong et al., 2014). Its use has been
widely beneficial in pre-clinical and clinical settings.

Fluorescence occurs when an excited molecule transitions from an excited state to
a relaxed state, emitting light. Fluorescent molecules, also called fluorophores, absorb
light in the visible range, and emit some of this light at a longer, less energetic
wavelength (Luker and Luker, 2008). Not all excited molecules emit light when reaching
the ground state. Most undergo a non-radiative vibrational relaxation, with only a small
portion of excited molecules emitting light. The efficiency of this process, the fraction of
excited molecules releasing photons during relaxation, is referred to as the quantum yield
(Birks, 1976). A simplified schematic showing these transitions can be found in the
Jablonski-Perrin diagram in Figure 1.3, as well as the original Jablonski diagram can also
be found (Jablonski, 1933; Valeur and Berberan-Santos, 2011).
8

A

B

Figure 1.3 Jablonski diagram for energetic transitions. Adapted from (Jablonski, 1933; Valeur
and Berberan-Santos, 2011). A. Scheme showing a simplified Jablonski-Perrin diagram. B.
Jablonski diagram from his 1933 Nature publication.

Fluorescence imaging relies on this principle to obtain information on tissues,
after light from an exogenous or endogenous fluorophore is detected. This imaging can
be direct imaging in which fluorophores are administered to target a specific biological
marker or indirect imaging, where transgenic specimens express a fluorescent marker
(Ntziachristos, 2006; Soubret and Ntziachristos, 2006). Direct imaging fluorophores can
be activated by a biological or metabolic response in tissue, such as enzyme cleavage
(Chiorazzo et al., 2015) or pH changes (Arroyo et al., 2019).

Although beneficial due to its wide range of applications, fluorescence imaging is
challenging in tissues because of tissue absorption and scattering, which occur on the
visible range, and because of autofluorescence of biomolecules such as flavins and
lipofuscins (Alves et al., 2017; Li et al., 2020). These problems have been partially
circumvented through the use of fluorophores in the near-infrared region (NIR) ranging

9

from 650 nm to 1700 nm, which include the NIR-I and NIR-II region, where tissue is
essentially transparent (Feng et al., 2021; Li et al., 2020).

Light detection through bioluminescence occurs when photons are produced after
a chemical reaction. For bioluminescence imaging, the most commonly used substrate is
the oxidation of luciferin by luciferase (Arranz and Ripoll, 2015; Ottobrini et al., 2016).
Bioluminescence is highly sensitive and does not require an external excitation source,
minimizing autofluorescence in vivo and increasing signal to noise ratio (Liu et al., 2011).

An additional modality of optical imaging which does not require an external
excitation source is Cerenkov Imaging, also referred to as Cerenkov Luminescence.
Cerenkov imaging bridges the gap between optical and nuclear techniques and present
several advantages for pre-clinical and clinical applications, such as radiation therapy
tracking. Cerenkov imaging can even be coupled with chromophores (Czupryna et al.,
2015) or fluorophores, creating a true multimodal imaging approach (Arroyo et al., 2019;
Das et al., 2014; Ottobrini et al., 2016).

1.6 Naphthofluorescein and Derivatives
Naphthofluorescein is a pH-dependent naphthoxanthene fluorophore that has a
maximum absorption λabs= 595 nm and a maximum emission of λem= 660 nm, which falls
within the NIR-I range (Lavis and Raines, 2008). The pKa of naphthofluorescein has been
reported to be 8.0 (Lavis, 2022; Lavis and Raines, 2008) and 7.6 (2022d; Chiorazzo,
2016) which is slightly above the physiological range for in vivo applications. 5(6)10

Carboxynaphthofluorescein is a naphthofluorescein derivative, which is also pHdependent, with highly similar optical properties as naphthofluorescein, with a maximum
absorption λabs= 572 nm and a maximum emission of λem= 668 nm and a pKa of 7.6 (Han
and Burgess, 2010).

The pH-sensitivity of carboxynaphthofluorescein, like naphthofluorescein, relies
on the equilibrium between protonated and deprotonated species, as seen in Figure 1.4,
and described by the Henderson-Hasselbalch equation (Po and Senozan, 2001; Radić and
Prkić, 2022). The protonated species exhibits a carboxylic function in the 5(6) position,
while the deprotonated species exhibits a lactone in the same position, resulting in
photophysical changes. These photophysical changes allow fluorescence when the
predominant species is the deprotonated molecule, which has a blue color. In acidic
conditions, there is no fluorescence (Le Guern et al., 2020; Martin and Lindqvist, 1975).

Figure 1.4 pH equilibrium of 5(6)-carboxynaphthofluorescein. 5(6)-carboxynaphthofluorescein
exhibits photophysical changes based on the equilibrium between its protonated (not-fluorescent) and
deprotonated species (fluorescent).
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1.7 Cerenkov Radiation
Cerenkov Radiation, also spelled Cherenkov, is a phenomenon that occurs when
charged particles travel faster than the speed of light in a dielectric medium
(L'Annunziata, 2016). In simple terms, a charged particle, generated through the decay of
a radionuclide, traveling faster than the speed of light in a specific medium is able to
transfer kinetic energy to that medium, which then relaxes though the emission of light
(Das et al., 2014).

Cerenkov radiation was first observed by Madame Curie in 1910, where she
described a faint blue glow coming from the bottles she kept, which contained radium
(Jennings, 1962). It wasn’t until 1933 that this phenomenon was formally described by
Pavel Cerenkov. He won the Nobel Prize in 1958, alongside Ilya Frank and Igor Tamm,
who proposed the mathematical framework for Cerenkov radiation (2022e; Čerenkov,
1937; Frank and Tamm, 1937; Pratt et al., 2021). In the present day, Cerenkov radiation
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may be observed by the naked eye in the pools where radioactive spent fuel is stored,
which emit a blue light as seen in Figure 1.5 (radioactivity.eu.com, 2022).

Figure 1.5 Cerenkov radiation in nuclear pool. Cerenkov radiation seen with the naked eye in
a nuclear reactor pool, where radioactive spent fuel is stored. Adapted from
(radioactivity.eu.com, 2022) "Radioactivity: Cherenkov Effect." from
https://www.radioactivity.eu.com/site/pages/Cherenkov_Effect.htm.

Cerenkov radiation has several properties that must be described and explained.
The particles that can produce Cerenkov radiation are charged subatomic particles such
as high energy β+ positrons or β- electrons. Cerenkov radiation can also be seen from α
emitters, but this radiation mainly comes from β emission from daughter radionuclides
(Das et al., 2014). As mentioned before, these fast particles polarize the medium, which
in turn emits photons as it undergoes relaxation. This light emission occurs in a
wavefront that travels in a cone (Figure 1.6), following the Huygens construction (Das et
al., 2014), with an angle described by equation 1.1. β is the velocity of the charge and n is
the refractive index of the medium (Ciarrocchi and Belcari, 2017; Jelley, 1955).

cos θ = 1/ βn

Equation 1.1
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Figure 1.6 Huygens propagation of light waves. The Huygens construction can be applied
to the wavefront produced by Cerenkov emission (Jennings, 1962). Adapted from (Das et al.,
2014).

In Cerenkov radiation, the number of photons emitted within a spectral range is
described by the Frank-Tamm formula (Equation 1.2), where α is the fine structure
constant (1/137) (Daniel LJ Thorek, 2012; Frank and Tamm, 1937). This equation
explains why Cerenkov radiation is blue-weighted, since its intensity is proportional to
the inverse of wavelength squared. As mentioned previously, Cerenkov radiation also

dN

=2πα 1dx

1
β2 n2

λ2 1
dλ
λ1 λ2

Equation 1.2

has an inverse relationship to the refractive index of the medium in which the charged
particles are traveling through. A larger refractive index corresponds to increased
Cerenkov emission. However, for Cerenkov radiation to be produced in a medium, the
traveling particles must meet the threshold energy for that medium, according to its
refractive index. For example, for Cerenkov emission to occur in water (n= 1.33) the
kinetic energy of the traveling particles must be at least 263 keV (threshold energy)
(Beattie et al., 2012; Das et al., 2014; L'Annunziata, 2016).
14

Cerenkov emitters have different end point energies, or maximum kinetic energy,
which relate to the probability of the Cerenkov emitters of producing enough energy to
reach the threshold energy (Das et al., 2014; Mitchell et al., 2011). The efficiency of
Cerenkov Radiation production can be summarized as 90Y > 68Ga > 15O > 11C > 124I
> 89Zr > 18F > 64Cu (Thorek et al., 2012). This information aids in choice of Cerenkov
emitter for specific applications.

1.8 Cerenkov imaging
Cerenkov radiation is continuous and includes the visible spectrum (Thorek et al.,
2012). It can be detected with sensitive charge-couple device (CCD) cameras, allowing it
to be used as an optical imaging modality. In 2009, Robertson et al. described the use of
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F-FDG, a clinical PET tracer, for Cerenkov imaging (also known as Cerenkov

Luminescence Imaging (CLI)), in vivo (Das et al., 2014; Robertson et al., 2009). The first

A

B

Figure 1.7 Clinical Cerenkov imaging. A. First human Cerenkography of patient with
hyperthyroidism treated with 131I. Adapted from (Spinelli et al., 2013). B. Cerenokv imaging of
axillary lymph node malignancy in a patient with lymphoma treated with 18F-FDG. Adapted from
(Thorek, Riedl et al. 2014).
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report of clinical use of Cerenkov imaging was in 2013, where Cerenkov was used to
monitor 131I in a patient being treated for hyperthyroidism, seen in Figure 1.7.A (Spinelli
et al., 2013). The Grimm group also demonstrated clinical Cerenkov imaging, identifying
an axillary lymph node in a patient with lymphoma treated with 18F-FDG, seen in Figure
1.7.B (Thorek et al., 2014a).
Cerenkov imaging provides an avenue to visualize clinically approved
radiotracers, merging nuclear imaging with optical imaging (Das et al., 2014). These
radiotracers have been modified with targeting moieties, nanoparticles and small
molecules for tumor identification, tumor margin delineation, and assessment of
metabolic markers (Arroyo et al., 2019; Bagguley et al., 2020; Boschi et al., 2011;
Czupryna et al., 2015; Holland et al., 2011; Lewis et al., 2018; Lohrmann et al., 2015;
Thorek et al., 2013). This imaging modality has several advantages: it is inexpensive,
high-throughput and does not require an external light source (Daniel LJ Thorek, 2012).
Additionally, CLI can produce a measurable signal quickly and it is proportional to PET
signal (Desvaux et al., 2018).

There are some challenges associated with CLI. The intensity of the Cerenkov
signal depends on the radionuclide of choice since its endpoint energy and half-life will
dictate the brightness and length of the signal. This choice must be made wisely. For
example, 18F has a half-life of 110 minutes, which is suitable for longer experimental
procedures. On the other hand, 68Ga has a half-life of only 68 minutes, which makes it
suitable for shorter experimental procedures. 68Ga, however, has a higher endpoint energy
than 18F (1899 keV and 633 keV, respectively), making the former a brighter emitter
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(Ciarrocchi and Belcari, 2017; Jimenez-Mancilla et al., 2019). This is a trade-off that
must be taken into account. Additionally, Cerenkov radiation produces relatively low
light compared to fluorescence (Thorek et al., 2012) and it is a blue-weighted emission,
which is highly absorbed by tissue (Ciarrocchi and Belcari, 2017; Soubret and
Ntziachristos, 2006).

Cerenkov photons can be transferred to longer wavelengths through Cerenkov
Radiation Energy Transfer (CRET) or Secondary Cerenkov Induced Fluorescence
Imaging (SCIFI), minimizing attenuation effects by moving the emission to longer
wavelengths where tissue is more permeable to light (Bernhard et al., 2014, 2017;
Dothager et al., 2010; Thorek et al., 2013). CRET occurs when a Cerenkov emitter is
coupled to a fluorophore. This fluorophore absorbs Cerenkov photons, provided by the
Cerenkov emitter, and undergoes fluorescence emission at longer wavelengths. This
process turns Cerenkov emitters into “internal lightbulbs”, providing the fluorophores
with the energy necessary to absorb and fluoresce, without the need of an external
excitation source.

The first step of this process is the absorption of Cerenkov photons by the
fluorophore, which results in a measurable signal attenuation. This attenuation is
described as Selective Bandwidth Quenching (SBQ) and was first proposed by our lab in
2015 to obtain functional information regarding pH using chromophores as pH indicators
(Czupryna et al., 2015). This attenuation is selective because it will occur at the
wavelength at which the dye absorbs, and it will be based on a functional metabolic
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response. For example, Czupryna et al. applied 18F labeled cresol purple and
phenolphthalein, to in vitro and in vivo models. These dyes showed selective attenuation
at their maximum wavelengths of absorption, in response to pH (Czupryna et al., 2015).
In another example, Arroyo et al. demonstrated SBQ using resazurin, which reports on
redox status, absorbing and fluorescing only when it is in its reduced state (Arroyo et al.,
2021). For Cerenkov signal modulation involving only SBQ, chromophores and not
fluorophores should be used, to prevent photon transfer that results in CRET.

CRET has been explored to enhance signal in tissues by transferring Cerenkov
photons to areas closer to the NIR window, where light is not as susceptible to tissue
effects (Bernhard et al., 2017). This photon transfer will also be able to provide
measurable information on a desired metabolic target, given that the correct reporter is
used. In Figure 1.8, we give an example of pH dependent SBQ and CRET, adapted from
(Arroyo, 2019; Arroyo et al., 2019). The spectrum in Figure 1.8.A shows the results from
a Cerenkov imaging study where the average radiance signal is plotted as a function of
wavelength at pH 6.4 and pH 8 for naphthofluorescein. An 18F-FDG control is included.
Robust SBQ is observed as a dip in the Cerenkov spectrum at 600 nm, at pH 8. CRET is
observed at 700 nm, as an increase in signal at pH 8. pH dependent SBQ and CRET can
be visualized directly as a change in brightness as a function of pH, as seen in Figure
1.8.B.
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Figure 1.8. Naphthofluorescein pH dependent SBQ and CRET. A. Cerenkov spectra of
naphthofluorescein at pH 6.4 and pH 8. 18F-FDG control is included. SBQ is observed at 600
nm. CRET is observed at 700 nm. B. pH titration of naphthofluorescein with 18F-FDG shows
signal decrease as a function of pH for SBQ and signal increase as a function of pH for CRET,
seen as darker and brighter wells, respectively.

1.9 Scope of thesis
The main focus of this thesis is the development and application of a Cerenkovactive pH sensitive probe that can report on tumor microenvironment pH in vivo. This
thesis presents the continuation of methods previously explored in our lab (Arroyo et al.,
2021; Arroyo et al., 2019; Czupryna et al., 2015; Kachur et al., 2017) for the application
of Cerenkov imaging for pH determination. This was done by developing a molecular
construct which includes 68Ga, a higher-endpoint energy emitter than 18F, chelated to a
carboxynaphthofluorescein based conjugate.

The second aim of this thesis is to understand the particular tissue effects that play
a role in the detection of pH sensitive SBQ and CRET, and how this data can be
interpreted and applied to obtain accurate Cerenkov pH values. Experimental Cerenkov
pH titration curves were interpolated to obtain in vivo pH values using CRET ratios
(Dothager et al., 2010). Efforts were dedicated to elucidating whether this technique can
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be accurately described as quantitative, in its current stage, and progress was done to
determine depth penetration and signal contributions from our fluorophore vis-à-vis 68Ga.

Cerenkov imaging provides an exciting framework within optical imaging due to
its expansive potential as a pre-clinical and clinical tool. With this work, we hope to
contribute to this field by providing a new application.
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Chapter 2
Methods

2.1 Materials
Acetonitrile, triethylamine, trifluoroacetic acid and naphthofluorescein were purchased
from Sigma-Aldrich. Dichloromethane, methanol, hydrochloric acid (1.0 N) and sodium
hydroxide (0.1 N) were purchased from Fisher Scientific. Ethanol was purchased from
Decon Laboratories, Inc. Millipore water was generously donated by Dr. Robert Mach.
5(6) Carboxynaphthofluorescein succinimidyl ester was purchased from Setareh Biotech.
4-Aminobutyl-DOTA was purchased from Macrocyclics.

Radioactive Gallium was obtained from the Cyclotron Facility at the University of
Pennsylvania, and later from Five Eleven Pharma, Inc.

MDA-MB-231 cell lines were purchased from the American Type Culture Collection
(ATCC). 4175-Luc+ cell lines were generously donated by Dr. Andy Minn (Minn et al.
2005).

LDHA and LDHB rabbit polyclonal antibodies were purchased from AbCam. IRDye ®
800 CW goat anti-rabbit IgG was purchased from LI-COR. Hoechst 33342 was
purchased from Invitrogen. Athymic NCR nu/nu 01B74 were purchased from Charles
River, Production. Lactate Dehydrogenase Inhibitor (LDHi), GSK 2837808A was
purchased from TOCRIS.
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2.2 High Performance Liquid Chromatography (HPLC)
Purification of non-radioactive compounds synthesized in-house was performed on a
Waters Alliance e2695 HPLC with a reverse-phase column (Phenomenex Synergy 4µ
Hydro-RP 80 A 10x250 mm). The product was resuspended in 1 mL 50% acetonitrilewater solution and injected into the HPLC. Elution was completed with a 95%-5%
solution of water-acetonitrile with 0.1% trifluoroacetic acid for 40 minutes with UV
absorption detection at 230 nm and fluorescence detection at 600 nm/660 nm. The peak
of interest was collected from minute 30 to minute 36. Acetonitrile was removed from the
collected fraction by rotary evaporation or by nitrogen gas. The remaining volume was
lyophilized for 24 hours using a Labconco FreeZone 4.5 lyophilized.

2.3 1H Nuclear Magnetic Resonance (NMR) Spectroscopy
Proton NMR Spectroscopy was performed to characterize NFbD after synthesis. This was
done on a Bruker DMX 500 by dissolving 10 mg of NFbD in 600 µL of deuterated water
buffered to pH 14 using NaOD. NMR spectra were acquired using the TopSpin software.
After running a standard (D2O), the sample was inserted into the NMR and locked in.
Shimming on this instrument was automatic. Proton MR spectra were collected using the
pulse sequence zgpr following acquisition parameters: relaxation delay (D1): 6, number
of scans: 128. Line broadening of 0.5 Hz was performed before Fourier transformation.
Data was analyzed using MestreNova Software (Mestrelab Research), using the residual
water solvent peak as reference.

22

2.4 Mass Spectrometry
Mass spectrometric analysis of synthesized products was performed using a Bruker
MALDI-TOF at the Mass Spectrometry Facility of the Department of Chemistry. A 10
mg/mL solution of alpha-cyano-4-hydroxycinnamic acid (CHCA) mixed with a 50:50
solution of acetonitrile and water and 0.1% trifluoroacetic acid was prepared. Samples
were placed on an MTP AnchorChip TM 600/384 TF MALDI target by adding 1 µL of
CHCA solution to the plate. Once the CHCA was dry, 1 µL of sample was added to the
dried CHCA and allowed to dry. Finally, a last 1 µL of CHCA was added on top of the
sample. This was mixed and let dry to form crystals. The target was inserted into a
Bruker Ultraflex MALDI-TOF/TOF mass spectrometer and irradiated by a Smartbeam II
laser at 200 Hz.

2.5 Cell Culture
MDA-MDA-231, a triple negative breast cancer cell line, and 4175-Luc+, a metastatic
variant of MDA-MB-231 generously donated by Dr. Andy Minn, were cultured with
Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine
serum (FBS) (GE HyClone Laboratories), 1% penicillin-streptomycin (P/S) (Mediatech)
and 1% L-glutamine (Mediatech). In addition, for 4175-Luc+ cell culture, 5 µg/mL
blasticidin (Invitrogen) was added for selection of the luciferase transfected cells. Cells
were maintained in a humidity-controlled incubator at 37º C under 95% air:5% CO2. Cell
passage was done when confluence reached 90% by aspirating media, washing with
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Phosphate Buffered Saline (PBS), adding 1 mL of 0.25% Trypsin (Thermo Fisher), and
neutralizing with culture media. Cell passage was done in a 1:10 ratio.

2.6 Cell Metabolism Experiments
To evaluate cell acidification, MDA-MB-231 cells and 4175-Luc+ cells were plated at
5x104, 1x105 and 5x105 cells per well in 3 separate 6-well plates in 3 mL DMEM. These
cells were incubated for 5 days, media was collected, and media pH was measured with
an Orion Star A111 (Thermo Fisher) pH meter.

To evaluate cell acidification in phenol red free media, MDA-MB-231 cells and 4175Luc+ cells were plated at 5x105 cells per well in separate 6-well plates using 3 mL
regular DMEM. After allowing for adhesion, media was aspirated from each well, cells
were washed with PBS, and 3 mL Seahorse XF Media (Agilent) was added, and cells
were incubated for 24 hours. The Seahorse XF Media was prepared with 10% FBS, 1%
P/S, 10% L-glutamine, 5 mM HEPES and either no glucose, low glucose (1 g/L) or high
glucose (4.5 g/L). Media from each condition was collected and pH was measured using
an Orion Star A111 pH meter.

To evaluate cell acidification in unbuffered media, MDA-MB-231 cells and 4175-Luc+
cells were plated at 1 x106 cells per well in separate 6-well plates using 3 mL regular
DMEM. After allowing for adhesion, media was aspirated from each well, cells were
washed with PBS, and 3 mL Seahorse XF Media was added. The Seahorse XF Media
was prepared with 10% FBS, 1% P/S, and 25 mM glucose. Cells were allowed to
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incubate in Seahorse XF Media for 24 hours and then media was collected to measure pH
using an Orion Star A111 pH meter. This media was later injected into a YSI 2300 STAT
PLUS Glucose & L-Lactate Analyzer to evaluate glucose and lactate levels.

To evaluate the effects of LDH inhibitors on glucose and lactate concentration, 4175Luc+ cells were plated in triplicate at 3x105 cells per well in 4 mL of regular DMEM in a
6-well plate. Cells were left to adhere overnight; media was aspirated and cells were
treated with 2-(3-phenyl-5-(trifluoromethyl)-1H-pyrazol-1-yl)thiazole-4-carboxylic acid
(Rai et al. 2017) or GSK 2837808A at 50 µM. Media was collected every hour for 6
hours and after 24 hours. Collected media was injected into a YSI2950 immobilized
enzyme analyzer (YSI Life Sciences) to evaluate glucose consumption and lactate
production.

2.7 Cellular Uptake Experiments
2.7.1 Fluorescence Microscopy
4175-Luc+ cells were plated in triplicate in 1 mL regular DMEM at 1x104 cells per well
in a 24-well plate. After 48 hours, and 3 hours before analysis, the media was changed to
phenol red free, full DMEM media. 681 µL of 8.1 µM NFbD was added to the cells to a
final concentration of 3.3 µM and incubated for 45 minutes. Hoechst stain was used as a
positive control, with a 3.5 µM final concentration. After treatment, the media was
removed, wells were rinsed with PBS and 1 mL fresh media was added. For microscopy
the ThermoFisher EVOS FL Auto 2 at the Cell & Developmental Biology (CDB)
Microscopy Core was used. NFbD was visualized under the Cy5 LED light cube, and
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Hoechst was visualized under the DAPI LED light cube. Images were obtained with light
at 25, exposure at 0.015 seconds and a gain of 1.0.

2.7.2 Absorbance Spectroscopy
4175-Luc+ cells were plated in triplicate in regular DMEM at 1 x104 cells per well in a
96-well plate. Cells were allowed to adhere for 24 hours; media was aspirated, and cells
were washed with PBS. After washing, cells were treated with a 4 µM, 2.8 µM or 1.6 µM
NFbD and incubated for 30 minutes. The medium was then aspirated, and cells were
washed with 0.5 mL of PBS twice. Cells were treated with 100 µL Triton X-100 0.5% or
PBS for 5 or 10 minutes. Absorbance was measured at 600 nm.

2.8 Cell Survival Experiments
To evaluate effects of NFbD on MDA-MB-231 and 4175-Luc+ cell survival, cells were
plated in triplicate at 7.5x104 cells per well in 96-well plates. A 0.5 mM stock solution of
NFbD was prepared in PBS. 5 µM, 1 µM 500 nM, 50 nM, 10 nM or 5 nM solutions in
media were prepared from the 0.5 mM stock to treat MDA-MB-231 or 4175-Luc+ cells.
Cell survival was evaluated through a thiazolyl blue tetrazolium bromide (MTT) assay.

To evaluate effects of LDH inhibitors on 4175-Luc+ cell survival, cells were plated in
triplicate at 1x104 cells per well in regular DMEM in a 96-well plate. Cells were left to
adhere overnight; media was aspirated, and cells were treated with 2-(3-phenyl-5(trifluoromethyl)-1H-pyrazol-1-yl) thiazole-4-carboxylic acid (Rai et al. 2017) or GSK
2837808A. A 1 mM solution of each LDHi was prepared in 1% DMSO dissolved in PBS.
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Cells were treated with 200 µM, 100 µM, 50 µM, 25 µM and 12.5 µM and cell survival
was evaluated through a Cell Titer Glo assay.

2.9 In vivo Experiments
2.9.1 Anesthesia
Prior to in vivo experiments, female Athymic NCR nu/nu mice were placed inside an
induction chamber and were anesthetized using 4% isoflurane. Mice were kept under
anesthesia at 2% isoflurane during optical and nuclear imaging experiments.

2.9.2 Euthanasia
Mice were placed in a container and put inside a closed CO2 chamber for 4 minutes. The
chamber and CO2 systems were provided by the University Laboratory Animal
Resources (ULAR). Euthanasia was confirmed by cervical dislocation.

2.9.3 Tumor Inoculation
MDA-MB-231 or 4175-Luc+ cells were grown in regular DMEM until confluent and
counted after trypsinization. The cells were centrifuged, media were aspirated and cells
were resuspended in PBS at a concentration of 2 x107 cells/ml. Matrigel ® (Corning) was
added in a 1:1 volume ratio to the cell solution. 100 µL of the final solution containing
1x106 cells was injected subcutaneously into either the right shoulder flank or the right
thigh of the mice. Mice were monitored to assess health and tumor growth. MDA-MB231 tumors were palpable after 3 weeks, while 4175-Luc+ tumors were palpable after 1-2
weeks post inoculation.
27

2.9.4 Intratumoral Injections
Mice were anesthetized, the area was sterilized with an alcohol wipe (70% isopropanol)
and the specified solutions were injected into the middle of the tumor. The plunger of the
syringe was pushed slowly to prevent effects from the interstitial pressure of the tumor,
such as treatment release due to back pressure.

2.9.5 Intravenous Injections
Mice were anesthetized, the tail was sterilized with an alcohol wipe (70% isopropanol)
and the specified solutions were injected into the tail vein. To aid with injection, the tail
was covered with warm compresses for a few seconds, causing vasodilation. The plunger
on the syringe was pushed carefully, when no resistance was felt, to guarantee
intravenous delivery.

2.9.6 31Phosphorus-Magnetic Resonance Spectroscopy (MRS)
Magnetic Resonance spectroscopy was performed in collaboration with Dr. Kavindra
Nath. These experiments were done on a 9.4 T/31 cm horizontal bore Bruker system. In
vivo 31P MR spectra (MRS) were acquired with a custom-built dual-frequency (1H/31P)
slotted-tube resonator (10 mm in diameter). To monitor mouse heart rate and core body
temperature, sub-dermal needle electrodes and a rectal thermistor were placed in the
mouse. The animal’s core body temperature was maintained at 37 ± 1°C. This was done
by blowing warm air into the bore of the magnet during the scan with heating controlled
by a thermal regulator system. A respiration pillow was placed under the thorax to
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monitor respiration. A 26-gauge intraperitoneal catheter was inserted into the peritoneum
prior to placing the mouse in the magnet, for 3-APP injection.

The magnet was shimmed until the 1H water line width of the subcutaneous tumor
reached 60–70 Hz. A point resolved spectroscopy (PRESS) sequence was obtained with
the following parameters: TR of 2 sec; TE of 20 ms; number of averages equal to 4. A
scan time of 8 sec, was used to shim a tumor voxel of 250-300 mm3 size to 30-40 Hz line
width. 31P MR spectra were obtained using an ISIS (Image Selected In vivo
Spectroscopy) sequence on this volume. The ISIS sequence employed slice-selective
hyperbolic secant inversion pulses with the following parameters: length of 0.59 ms; 256
scans with a 7 µs radiofrequency pulse width at 200 watts, corresponding to
approximately a 90º flip angle; acquisition band width of 7978.2 Hz; 512 acquisition
points; TR of 4 s; total acquisition time of 7 minutes 4 seconds.

Following acquisition of baseline 31P MR spectra, 3-aminopropylphosphoninc acid (APP;
300 mg/ml) was injected intraperitoneally through the intraperitoneal catheter without
removing the animal from the magnet. 31P spectra were collected again as described
above, 20 minutes after 3-APP injection.

2.9.7 Dynamic Positron Emission Tomography Scan
NFbD-68Ga (up to 1.48 MBq), was injected intravenously via tail vein into mice bearing
4175-Luc+ breast cancer tumor xenografts. Mice were imaged dynamically in the
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Molecubes β-Cube for 2 hours. This was followed by a CT-Scan that was run for 3
minutes using the Molecubes X-Cube (Ghent, Belgium).

PET images (24 frames at 5 minutes per frame) were reconstructed into 192 x 192 x 384
(x,y,z) slices with 0.4 mm voxels with frame lengths of 24 x 300 seconds. All corrections
were applied using a manufacturer supplied reconstruction program. CT images (50 kVp
and 100 µA) were reconstructed into 200 x 200 x 550 (x,y,z) slices with 0.2 mm voxels
with a manufacturer supplied reconstruction program.

2.10 Protein Immunoblot
To determine LDHA and LDHB expression ex vivo, MDA-MB-231 and 4175-Luc+
tumors were excised from euthanized mice when they were around 1 cm3. These tumors
were weighed, flash frozen and homogenized using 1 mL of RIPA buffer per 100 mg of
tissue in a Potter-Elvehjem Tissue Homogenizer. Homogenized samples were subjected
to 3 freeze/thaw cycles using liquid nitrogen and a 37º C water bath, respectively. Finally,
the samples were sonicated for 15 minutes, let sit on ice for 15 minutes and centrifuged
for 10 minutes at 14,000 g. The supernatant from this step (cell lysate) was saved and
protein concentration measured using a bicinchonic acid (BCA) protein assay kit (Pierce).
Samples were diluted in a 1:1 ratio with Laemmli Loading Buffer (Bio-rad), containing
5% 2-mercaptoethanol and then heated at 95º C for 5 minutes. 10% Mini-PROTEAN
SDS-PAGE gels (Bio-rad) were loaded with 30 µL of each sample and electrophoresis
was ran at 300V for 18 minutes on a PowerPac Basic electrophoresis system (Bio-rad).
This gel was transferred to a nitrocellulose membrane (0.45 µm) (Invitrogen) using a
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Trans-Blot SD Semi-Dry Transfer Cell (Bio-rad). Ponceau S solution 0.1% w/v in 5% v/v
acetic acid (Sigma) was used to confirm the transfer and the gel was then washed with
PBS. The membranes were blocked using Odyssey Blocking Buffer (LI-COR) for one
hour and then incubated overnight with primary antibodies (LDHA, LDHB or β-tubulin
(Abcam)). Primary antibodies were diluted 1:1,000 in a blocking buffer solution with
0.2% Tween 20. After 24 hours, the membranes were washed and secondary antibodies,
diluted 1:15,000 in a blocking buffer solution with 0.2% Tween 20 (Sigma), were added
(goat anti-rabbit conjugated with IRDye ® 800 CW from LI-COR). Membranes were
imaged using the LI-COR Odyssey ® Clx Imaging System and analyzed with
ImageStudio Lite.

2.11 Optical Imaging
Optical imaging studies were performed using the PerkinElmer IVIS Spectrum. For
phantom studies, 96-black well plates with a flat clear bottom were used. Plates were
placed carefully inside the IVIS system, aligned with the field of view outline (seen as a
green light inside the chamber) in order to aid in grid ROI measurement. The
LivingImage software for the IVIS Spectrum, the system was initialized, and then the
Cerenkov imaging parameter was chosen in the Imaging Wizard, followed by “Spectral
Unmixing”. For our purposes, the following bandwidth emission filters were chosen: 580
nm, 600 nm, 680 nm, 700 nm and 840 nm. Images were acquired with a Binning of 8
(M), Field of View (FOV) of 13.1, f1 and exposure of 60 seconds.
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For in vivo experiments, mice were placed on the heated stage inside the chamber, after
intratumoral injections of the appropriate solutions. Each mouse was placed on its side
with the tumor facing the camera, and ensuring that their snout was comfortable and
securely inside the nose cones for continued anesthesia. Acquisition parameters were as
following: Binning: 8 (M), FOV: 22.3, f1 and exposure time of 300 seconds. The images
were acquired using the same bandwidth filters as with the plate experiments.

2.12 Determination of Tissue Effects
To determine the effects of tissue on Cerenkov imaging, several tissue phantom models
were explored.

A black well, clear bottom 96-well plate was prepared with varying concentrations of
intralipid and/or India ink, 40 µM napthofluorescein, 50 µL 68Ga (~30 µCi/well) and 10
µL NaOH (1 N) to keep the conditions basic. Saline was added to each well to obtain a
250 µL volume per well. Conditions were plated in triplicate. This plate was imaged in
the IVIS Spectrum and analyzed using LivingImage Software.

A black well, clear bottom 96-well plate was prepared with 240 µM naphthofluorescein,
10 µL NaOH (1 N), 50 µL 68Ga and saline (added to achieve a final volume of 250 µL).
Conditions were plated in triplicate, with no naphthofluorescein as a control. This plate
was imaged in the IVIS Spectrum, then bologna slices (ACME) 2.5 mm, 3 mm or 6 mm
thick were placed on top of the wells, to determine tissue effects and depth penetration.
Imaging was repeated after bologna slices were placed on top of the wells.
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A black well, clear bottom 96-well plate was prepared with 240 µM naphthofluorescein,
50 µL 68Ga and citrate/borate/phosphate buffer (0.05 M) at pH 4, 7.4 or 8, added to
achieve a final volume of 250 µL. Conditions were plated in triplicate. This plate was
imaged in the IVIS Spectrum, and then tumor or skin slices excised from mice bearing
4175-Luc+ tumors were placed on top of the wells containing activity. Tumor slices were
around 2 mm thick and skin slices were around 1 mm thick. Imaging was repeated when
tissue was placed on top of the wells.

A black well, clear bottom 96-well plate was prepared with 240 µM naphthofluorescein,
50 µL 68Ga and citrate/borate/phosphate buffer (0.05 M) at pH 4, 7.4 or 8, added to
achieve a final volume of 250 µL. Conditions were plated in triplicate. This plate was
imaged in the IVIS Spectrum. 1 mm chicken slices were placed on top of wells
containing activity in an additive manner, until reaching 4 mm thickness. Chicken slices
were obtained from frozen chicken breast (ACME), sliced using a meat slicer set to 1 mm
thickness. Imaging was repeated with each addition of a chicken slice, for a total of 5
imaging cycles.

To determine tissue effects in vivo mice bearing 4175-Luc+ tumors were injected
intratumorally with 20 µL NFbD-68Ga (~27 µCi). These mice were imaged in the IVIS
Spectrum and euthanized. After euthanasia, the skin over the tumors was removed, and
imaging was repeated. Tumors were then excised and imaged, and finally, tumors were
sliced and imaged.
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2.13 In vivo pH modulation
Mice bearing 4175-Luc+ tumors were injected with 20 µL NFbD-68Ga (~35 µCi)
intratumorally and in the right thigh to evaluate pH response of NFbD in the acidic tumor
milieu, using the muscle as an internal control. Injected mice were imaged in the IVIS
Spectrum.

Mice bearing 4175-Luc+ tumors were injected intratumorally with 100 µL solution of
naphthofluorescein (110 µM) and ~22 µCi of 68Ga (pH adjusted with NaOH 0.1 N). Mice
were imaged in the IVIS Spectrum. After imaging, mice were injected intratumorally
with NaHCO3 (200 mM) to increase tumor pH. Imaging was repeated.

2.14 Statistical Analysis
Data was processed using Microsoft Excel and GraphPad PRISM. Data are presented as
mean ± standard deviation of triplicate values (n = 3), unless otherwise noted. Non-linear
regressions to obtain pH values were performed with GraphPad PRISM. Statistical
significance is defined as p-values lower than 0.05.
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Chapter 3
Naphthofluorescein-butyl-DOTA (NFbD)

3.1 Introduction

This chapter describes the synthesis of a pH-sensitive, Cerenkov-active imaging
molecule, capable of attenuating Cerenkov signal and producing subsequent CRET. This
probe, NFbD, is a naphthofluorescein derivative, which is pH-dependent and exhibits a
robust color change from fuchsia in the acidic or protonated form (pH < pKa) to bright
blue in the basic or deprotonated form (pH > pKa). This change in color can be exploited
to modulate Cerenkov radiation to enable relevant pre-clinical molecular imaging studies.

Cerenkov emitters such as 68 Ga and 90 Y emit Cerenkov radiation in a broad and
continuous frequency spectrum, with an intensity proportional to 1/λ2, which includes
visible light. These emitters, when coupled to a fluorophore like NFbD, act as an
“internal lightbulb” providing them with the energy necessary to absorb and fluoresce.
This kind of absorption and fluorescence selectively affect the continuous emission of the
Cerenkov spectrum. Selective Bandwidth Quenching, or SBQ is observed as a decrease
or attenuation of the signal in the Cerenkov spectrum at the wavelength at which the
fluorophore absorbs. Cerenkov Radiation Energy Transfer or CRET is observed as an
increase of the signal in the Cerenkov spectrum at the wavelength at which the
fluorophore fluoresces (Figure 3.1). These changes in signal can be detected with a
sensitive camera such as the CCD camera present in the PerkinElmer IVIS Spectrum.
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Figure 3.1 Scheme for the detection of pH dependent Cerenkov signals. A. A Cerenkov emitter
supplies the required energy to excite a linked fluorophore, acting as an “internal lightbulb”. This
absorption leads to Selective Bandwidth Quenching (SBQ) near the absorption maxima of the
fluorophore of choice. Cerenkov Radiation Energy Transfer (CRET) or Cerenkov-induced
fluorescence is observed near the emission maxima of the fluorophore. B. Example Cerenkov
spectra normalized to the 680 nm filter (isosbestic point of NFbD), exhibiting SBQ and CRET. C.
Example Cerenkov spectra normalized to the 840 nm filter (increased tissue penetration). pH
dependent signals can be obtained from SBQ and CRET measurements, when linking the Cerenkov
emitter to a pH sensitive fluorophore.

NFbD was designed as a second-generation Cerenkov active probe, which
incorporates a brighter Cerenkov emitter than the ones previously used in our lab, 18 F
(Arroyo et al., 2019; Czupryna et al., 2015; Kachur et al., 2017; Kachur et al., 2013a;
Kachur et al., 2013b). The molecular structure of NFbD includes a fluorophore, a linker,
and a chelator, all of which could be fine-tuned or replaced to obtain optimal properties
for the desired application. For this project, naphthofluorescein was our fluorophore of
choice because of its optical properties, price, and availability. DOTA was chosen as our
chelator because it can create coordination complexes with 68 Ga and 90 Y (Baranyai et al.,
2020). These Cerenkov emitters produce a brighter Cerenkov signal than 18 F, due to their
higher endpoint energies, aiding in signal detection (Ciarrocchi and Belcari, 2017).
36

3.2 Naphthofluorescein-butyl-DOTA (NFbD) Conjugation
Naphthofluorescein-butyl-DOTA (NFbD) results from the conjugation between
the fluorophore, 5(6)-Carboxynaphthofluorescein succinimidyl ester (CNF-SE) and the
chelator, 4-aminobutyl-DOTA (DOTA), which occurred through a nucleophilic
substitution. For this synthesis, 4.5 mg CNF-SE were dissolved in 10 µL triethylamine
(TEA) and 500 µL dichloromethane (DCM). 4.3 mg 4-aminobutyl-DOTA were dissolved
in 30 µL H2O and 480 µL methanol. The 4-aminobutyl-DOTA solution was added
dropwise to the CNF-SE solution, and left stirring for one hour at 25º C (room
temperature). The reagents in this reaction were added in a 1:1 molar ratio. This reaction
occurs optimally in the absence of water which is the reason mostly organic solvents
were used. 4-Aminobutyl-DOTA required water for dissolution, which was kept at a
minimum.

The product was dried under N2 to remove volatile organic solvents from solution,
and then lyophilized overnight. The dried product was resuspended in a 50:50 mixture of
acetonitrile/water and injected into a Waters Alliance e2695 HPLC with a reverse-phase
column (Phenomenex Synergy 4μ Hydro-RP 80 Å 10 x 250 mm), which ran for 40
minutes in a 95%-5% solution of water-acetonitrile with 0.1% trifluoroacetic acid with
collection from minute 30 to 36. This product was again dried under N2 to remove
acetonitrile and lyophilized, yielding a dark pink film. The product was weighed and
dissolved in the appropriate volume of ethanol to obtain a 1 mg/mL solution. This

37

solution was divided into 1 mL aliquots and the ethanol was dried under N2, obtaining
aliquots of 1 mg NFbD per vial.

3.3 NFbD Chelation with Gallium
Chelation of NFbD was first done with 69,71 Gallium, which is non-radioactive, to
prevent equipment contamination during characterization. 46 µL GaCl3 (1.14 M in 6 N
HCl) was added to NFbD (resuspended in 0.5 M ammonium acetate) in a 2:1 molar ratio,
to a total of 2 mL. This solution was stirred for 5 minutes, then heated for 5 minutes at
85- 90º C, and stirred for 10 minutes. 100 µL 1 N HCl was added to this solution to
obtain the product, which precipitated after 1 minute of centrifugation. Supernatant was
removed and the remaining pellet was dissolved in 1% ethanol/saline solution. This
solution was neutralized to pH 7 with NaOH before experimental applications.

The purpose of conjugating CNF-SE with DOTA was to create a pH sensitive
fluorophore that could incorporate a Cerenkov emitter in its structure. For this project,
our Cerenkov emitter of choice was 68 Gallium. To obtain this molecule, 1 mg NFbD was
resuspended in 500 µL 0.5 M ammonium acetate and 10 µL 0.5 N NaOH (to aid in
dissolution). 500 µL 68 Gallium was eluted in 4 mL 0.05 M HCl (~215 µCi), added to the
NFbD solution, stirred, and heated at 85- 90º C for 5 minutes. This solution was divided
into two 1.5 mL Eppendorfs tubes. 25 µL of 1 N HCl was added to each tube followed by
centrifugation at 6000 rpm for 1-2 minutes. NFbD is insoluble in acidic conditions, so the
addition of acid and further centrifugation resulted in the precipitation of the product,
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NFbD-68 Ga. The supernatant was removed and the product dissolved in the desired
volume of a 1% ethanol/saline solution for either in vitro or in vivo experiments.

3.4 Results
NFbD was obtained through a condensation reaction where the succinimidyl ester
in the CNF-SE was replaced by the amino group of the 4-aminobutyl-DOTA (Figure
3.2). This reaction was completed in one hour and was confirmed by MALDI-TOF,
where the parent ion peak was seen at 934 m/z+ (Figure 3.3). A peak is seen at 477 m/z+,
which corresponds to unreacted carboxynaphthofluorescein. The 379 m/z+ peak
corresponds to the matrix, CHCA. NFbD showed a maximum absorbance at λexc = 600
nm and a maximum emission at λem = 669 nm at basic pH (Figure 3.4A). NFbD also
maintained its pH sensitivity after conjugation, showing a pKa of 7.8 (Figure 3.4B,C).
The optical properties of NFbD are comparable to its parent compound

Figure 3.2 Synthetic scheme for NFbD and NFbD-Ga. 4-Aminobutyl-DOTA dissolved
in methanol/water was added dropwise to 5(6)-carboxynaphthofluorescein succinimidyl
ester dissolved in dichloromethane/TEA (1:1 molar ratio) and stirred for 1 hour to produce
NFbD. NFbD was purified by HPLC, lyophilized, and dissolved in ammonium acetate 0.5
M. For chelation, GaCl3 was added in excess, stirred, heated (85 ºC-90 ºC, 5 minutes),
stirred for 10 minutes) and precipitated with HCl.
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naphthofluorescein, which has an absorption maximum at λexc = 595 nm, maximum
emission at λem = 660 nm and reported pKa of 7.6-7.8 (2022d; Chiorazzo, 2016; Lavis,
2022; Lavis and Raines, 2008).

To determine photostability, fluorescence of NFbD was measured every 5
seconds for 18 hours at λexc = 600 nm/λem = 669 nm (Figure 3.4D). NFbD exhibited a
higher photostability than naphthofluorescein alone, which was used as a control. At a
concentration of 10.1 µM, NFbD had a photobleaching half-life (t1/2) of 967 minutes,
while naphthofluorescein at a concentration of 10.4 µM had a t1/2 of 531 minutes. Even at
higher concentrations, naphthofluorescein showed a decreased photobleaching half-life
(17.8 µM, t1/2= 851 minutes), as shown in Figure 3.4.
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Figure 3.4 Spectroscopic properties of NFbD. A. Absorbance and fluorescence spectra of
NFbD at pH 9, λexc = 599 nm, λem = 669 nm. B. Visual representation of pH-dependent color
change of NFbD, from its protonated (fuchsia) to unprotonated (blue) form. C. pH titration
of NFbD confirms pH sensitivity at physiologically relevant pH values, pKa = 7.8. D.
Photostability assay of NFbD at pH 9. Fluorescence was measured every 5 seconds for 18
hours at λexc = 600 nm, λem = 669 nm. NFbD shows higher photostability compared with
naphthofluorescein alone. NFbD (10.1 µM), t1/2 = 966.6 minutes, NF (10.4 µM), t1/2 = 531.4
minutes, NF (17.8 µM), t1/2 = 851.1 minutes.

NFbD was chelated with gallium, through a hexacoordinated complexation with
DOTA (Kubíček et al., 2010). This reaction was completed in less than 30 minutes and
was confirmed by MALDI-TOF with peaks at 1000 m/z+, 1002 m/z+ (NFbD+ 69, 71Ga).
MALDI-TOF also showed a significant peak at 547 m/z+ corresponding to a
hydrolyzation of NFbD with DOTA as a leaving group (Figure 3.5). NFbD-Ga
maintained optical properties, with a maximum absorbance at λexc = 600 nm, a maximum
emission at λem = 669 nm at basic pH. NFbD-Ga maintained pH sensitivity exhibiting a
pKa = 7.7 (Figure 3.6).
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68

Ga

Figure 3.5 MALDI-TOF of NFbD-Ga. NFbD-Ga peaks are seen at 1000.974 m/z+ (100%),
999.079 (92.63%) and 1002.905 (30.02%). Peak at 547.272 m/z+ (92.65%) corresponds to
hydrolyzed NFbD, with DOTA as a leaving group.

A

B

Figure 3.6 Spectroscopic properties of NFbD-Ga. A. Absorbance and fluorescence
spectra of NFbD at pH 9, λexc = 600 nm, λem = 669 nm. B. pH titration of NFbD-Ga
confirms pH sensitivity at physiologically relevant pH values, pKa = 7.7.
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3.5 Discussion
The purpose of this study was to develop a modifiable molecular scaffold which
included a bioactive fluorophore, a linker, and a chelator to obtain a Cerenkov-active
probe. A Cerenkov-active probe is defined as a molecule whose structure contains a
fluorescent moiety that is capable of absorbing and/or fluorescing due to the energy
provided by a Cerenkov emitter. Such a molecular construct would allow Cerenkov
imaging to be used for tracking desired metabolic responses in vitro and in vivo, such as
redox status and pH, without the need of an external energy source.

We were able to conjugate the fluorophore CNF-SE to the chelator 4-aminobutylDOTA, to obtain the pH-dependent, Cerenkov-active probe NFbD. This conjugation was
achieved through a condensation reaction in a one-step reaction with commercially
available reagents. While elucidating the optimal synthesis conditions for NFbD, we were
able to identify MALDI peaks that corresponded to hydrolysis, which led to the
determination of using only organic solvents in this reaction (data not shown). However,
4-aminobutyl-DOTA needed a small percentage of water to dissolve properly so the
reaction could take place. The MALDI corresponding to NFbD-Ga showed a
fractionation peak at 547 m/z+, corresponding to hydrolysis of NFbD, with DOTA as a
leaving group. This kind of spectroscopic analysis was greatly helpful in understanding
our reaction conditions, ultimately allowing us to troubleshoot and optimize to increase
efficiency.
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As desired, NFbD maintained the optical properties of its parent fluorophore,
naphthofluorescein, with absorption at λexc = 600 nm and emission at λem = 669 nm.
Absorption and emission wavelengths for NFbD are closer to the far red, which makes it
suitable for in vivo imaging. Additionally, NFbD maintained its pH sensitivity, crucial for
the success and progression of this project. For the capability of obtaining in vivo pH
measurements, the pKa of the fluorophores used should be close to physiological pH, 7.2.
Spectroscopic studies of NFbD showed a pKa of 7.8, which is slightly higher than
optimal. However, it has been shown that pKa measured through Cerenkov imaging
exhibits lower values (Arroyo, 2019; Arroyo et al., 2021; Arroyo et al., 2019; Czupryna
et al., 2015), as will be demonstrated in upcoming chapters. Finally, NFbD showed
increased photostability compared to naphthofluorescein, for reasons which are not
currently understood.

We were able to chelate NFbD with Ga in 30 minutes. This reaction needed to be
completed as quickly as possible since 68Ga has a half-life of 68 minutes. The detectable
signal obtained from Cerenkov imaging greatly depends on the amount of activity
present, which in turn depends on the time it takes for the isotope to go from the
generator to the IVIS Spectrum. Photoexcited molecules go through various relaxation
pathways, the most common of which is a vibrational transition which does not produce
fluorescence. If activity is low, the Cerenkov emitter will not be able to excite enough
molecules to warrant detectable fluorescence, and pH dependent signals will not be
measureable through CRET. We are interested in measuring CRET because it is a redshifted signal, ideal for in vivo imaging.
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Chelation with 69, 71Ga did not affect the pH sensitivity of NFbD nor its optical
properties, yielding a successful product, with λexc = 600 nm, λem = 669 nm and a pKa =
7.7. NFbD-Ga was characterized only in its non-radioactive form to prevent radioactivity
contamination to any equipment, and it was assumed that its optical properties would be
identical to those of its radioactive counterpart.

3.6 Conclusion
This chapter presented the one step synthesis of NFbD, followed by its “shake and
shoot” chelation with gallium. This Cerenkov-active probe was synthesized with the
purpose of expanding the applications of Cerenkov imaging in a pre-clinical setting.
NFbD is a molecule that absorbs and fluoresces in a pH-dependent manner by excitation
through an external energy source (laser) or by interacting with Cerenkov emitters, such
as gallium. This allows us to use Cerenkov imaging for pH determination, which can be
applied to studies of the tumor microenvironment in vitro and in vivo. In addition, NFbD
presents a molecular construct that can be fine-tuned to fit the needs of the desired
application, by substituting the bioactive fluorophore and/or the chelator, to obtain
Cerenkov signals pertaining to a different molecular target.
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Chapter 4
NFbD in vitro

4.1 Introduction
Cerenkov radiation occurs when a β-particle travels faster than the speed of light
in a dielectric medium, transferring its kinetic energy to adjacent particles which undergo
relaxation through light emission (Das et al., 2014). This light emission is continuous
and multispectral with an intensity proportional to 1/ λ2, which includes the visible
spectrum. When a Cerenkov emitter is coupled with a fluorophore, it will act as an
“internal lightbulb”, providing the energy necessary for the fluorophore to absorb and
fluoresce. This absorption and subsequent fluorescence cause a disruption to the
continuous Cerenkov spectrum, resulting in measurable signals that can correspond to
certain biological parameters such as pH, depending on the fluorophore of choice
(Arroyo et al., 2019).

Attenuation resulting from absorption of Cerenkov radiation is called Selective
Bandwidth Quenching (SBQ) and it occurs near the wavelength at which a chromophore
absorbs (Czupryna et al., 2015). Fluorescent molecules will also show a Cerenkovinduced fluorescence or Cerenkov Radiation Energy Transfer (CRET), an emission
following SBQ, near the wavelength at which the fluorophore emission occurs. CRET is
a valuable phenomenon for in vivo imaging because it results in a red shift of Cerenkov
photons, reducing the effects of tissue scattering and absorption in optical imaging
(Bernhard et al., 2017). For this project, NFbD, a naphthofluorescein derivative, was
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coupled with the Cerenkov emitter 68Ga with the purpose of detecting tumor
microenvironment (TME) pH in vivo. This probe was first tested in vitro, to confirm pHdependence and to establish cellular models of acidification.

In this Chapter, we test the ability of NFbD-Ga to act as a pH sensor in vitro and
in cell models. Our cell models consisted of the MDA-MB-231 and 4175-Luc+ cells,
triple negative breast cancer cell lines with varying expression of lactate dehydrogenase
A (LDHA), the enzyme responsible for catalyzing the conversion of pyruvate into lactate
(Luo et al., 2021). 4175-Luc+ cells express increased levels of LDHA, compared to
MDA-MB-231 cells, leading to the hypothesis that 4175-Luc+ would exhibit higher
acidification in vivo, due to increased co-secretion of lactate with a proton (Arroyo,
2019). Lactate dehydrogenase inhibitors (LDHi) were used as an alternative method for
pH modulation. TME acidification occurs after co-secretion of lactate with a proton
(Manzo-Merino et al., 2019). If the enzyme converting pyruvate to lactate is inhibited,
lactate production and secretion should decrease, decreasing acidification (Rai et al.,
2017). Establishing acidification or alkalization models would allow appropriate controls
to be considered when measuring pH through Cerenkov imaging.

4.2 Results
In vitro Cerenkov imaging was achieved with NFbD-Ga at physiologically
relevant pH values. A 96-well plate containing a phosphate, borate, citrate buffer (0.05
M) (Kachur et al., 2017) at pH 4, 6.4, 6.8, 7.0, 7.4 and 8 was prepared in triplicate (pH
adjusted with HCl or NaOH). ~100 µCi 68Ga were added to each well to detect pH
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dependent differences in Cerenkov radiation (Figure 4.1). pH-Dependent SBQ was
observed between the 580 nm filter and the 660 nm filter, with maximum SBQ observed
at 600 nm, close to the λmax abs for NFbD (600 nm). In Figure 4.1A, SBQ is visually
identifiable as the dark wells, as pH increases. At longer wavelengths (λ ≥ 680 nm),
CRET can be observed as brighter wells with increasing pH, Figure 4.1.A. Maximum
CRET occurs at 700 nm, which is red shifted from the λmax em for NFbD (669 nm).
Images obtained through Cerenkov imaging were quantified using the LivingImage
software from PerkinElmer, allowing pH-dependent Cerenkov spectra to be plotted, as
shown in Figure 4.1.B-C. These spectra illustrate the pH-dependent signal attenuation
and subsequent CRET that is produced when NFbD is in the presence of a Cerenkov
emitter, 68Ga. These data were normalized in two ways. First, ratios for the average
radiance at each point were calculated relative to the 840 nm filter, which is the
wavelength at most light penetration is expected in tissue (Figure 4.1.B). Additionally,
the ratio of average radiance for each point was calculated relative to the wavelength at
which maximum SBQ occurs, 600 nm, which greatly amplified the CRET signal, aiding
in signal visualization (Figure 4.1.C).
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Figure 4.1 pH dependent intermolecular Cerenkov imaging of NFbD. A. Cerenkov image of
NFbD mixed with ~100 µCi 68Ga at various pH values. The maximum SBQ is observed at 600 nm
due to absorption of Cerenkov radiation by NFbD in basic form. The maximum CRET is observed
between 700 nm and 720 nm. B. Cerenkov spectrum at various pH values of NFbD mixed with
68
Ga, normalized to 840 nm filter. C. Cerenkov spectrum at various pH values of NFbD mixed with
68
Ga, normalized to 600 nm filter.
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Figure 4.2 Intermolecular Cerenkov pH titration curve for NFbD with 68Ga. A. pH titration
curve at maximum CRET (700 nm), normalized to 840 nm filter. CRETinter pKa (840nm) = 7.07.
B. pH titration curve at maximum CRET (700 nm), normalized to 600 nm filter. CRETinter pKa
(600 nm) = 7.28.
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Cerenkov spectra were then plotted as the average radiance ratio as a function of
pH, to allow for interpolation of in vivo pH values, as seen in Figure 4.2. These graphs
were plotted using the Cerenkov signals obtained with the 700 nm filter, providing CRET
pKa values (CRETinterpKa (840 nm) = 7.07, CRETinterpKa (600 nm) = 7.28). As mentioned in the
previous chapter, these pKa values were lower compared to the pKa vales obtained
through spectroscopy.

The Cerenkov spectra and pH titration curves in Figures 4.1 and 4.2 showed
intermolecular Cerenkov signals (NFbD mixed with 68Ga). Figure 4.3 shows spectra and
titration curves constructed using intramolecular Cerenkov signals, where 68Ga was
chelated into NFbD, producing NFbD-Ga. SBQ and CRET patterns were identical to
those observed intermolecularly, with a decreased CRET intensity (Figure 4.3.A-B). This
could be due to 68Ga and NFbD molecules having less interactions resulting in
fluorescence when chelated than when mixed. CRET pKa values were obtained for
intramolecular Cerenkov, as in the previous figure (Figure 4.3.C-D) (CRETintrapKa (840 nm)
= 7.58, CRETintrapKa (600 nm) = 7.50). Although this phenomenon needs to be explored
further, studies have shown that CRET is dependent on fluorophore concentration and the
activity of the Cerenkov emitter, seen in Figure 4.4. CRET efficiency, defined as the ratio
of the signal obtained at 700 nm to the signal obtained at 600 nm (CRET/SBQ), is
proportional to fluorophore concentration and to Cerenkov emitter activity.
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Figure 4.3 Intramolecular Cerenkov imaging of NFbD with 68Ga. A. Intramolecular
Cerenkov (chelated NFbD-68Ga) spectrum of ~ 80 µCi NFbD-Ga at different pH values,
normalized to 840 nm filter. B. Cerenkov spectrum normalized to 600 nm filter. SBQ
and CRET are observed at 600 nm and 700 nm, respectively. C. Cerenkov pH titration
curve of A. CRETinter pKa (840nm) = 7.58. E. Cerenkov pH titration curve of B. CRETinter
pKa (600nm) = 7.50.

25 0
00
.0

0

0.

50

0

0.

25

.5

5.

12

0.

62

0

0

NFbD Concentration (µM)

2

0

68Ga Activity

37
.9
0

2

4

25
.3
0

4

6

12
.6
0

6

6.
30

CRET Efficiency (CRET/SBQ)

B
CRET Efficiency (CRET/SBQ)

A

(µCi)
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NFbD was characterized in vitro using two triple negative breast cancer cell lines:
MDA-MB-231 and its metastatic variant, 4175-Luc+. As mentioned previously, these are
aggressive cancer cell lines with varying expression of LDHA, which catalyzes the
conversion of pyruvate to lactate and whose co-secretion with a proton decreases
extracellular pH in tumors. 4175-Luc+ cells express higher LDHA levels compared to
MDA-MB-231 cells (Arroyo, 2019). This difference in LDHA expression led to the
hypothesis that 4175-Luc+ would have a higher acidification rate than MDA-MB-231,
providing potential in vitro and in vivo models of acidification.

First, the toxicity of NFbD was determined. MDA-MB-231 and 4175-Luc+ cells
were treated with increasing concentrations of non-radioactive NFbD-Ga and cell
viablility was determined with the MTT assay. The results showed no changes in cell
viability at concentrations up to 5 µM, as seen in Figure 4.5, suggesting that NFbD-Ga is
not toxic to these cell lines.
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Figure 4.5 NFbD-Ga cell toxicity in vitro. MDA-MB-231 and 4175-Luc+ (7.5 x 104
cells/well) were treated with non-radioactive NFbD-Ga (5 nM -5 µM). Cell viability was
measured using the MTT assay, which showed no cell toxicity.
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After evaluating toxicity, cellular uptake of NFbD was assessed. Fluorescence
microscopy was performed on 4175-Luc+ cells treated with NFbD (3 µM), which
showed no intracellular uptake after a 45-minute incubation, Figure 4.6.A. Hoechst, a
nuclear stain, was used as a positive control. These results were further confirmed by
incubating 4175-Luc+ (1.0 x 104 cells/well) cells with varying concentrations of NFbD
for 30 minutes, followed by rinsing with PBS and then treating them with Triton X-100
(0.5%) for 5 or 10 minutes, Figure 4.6.B. No changes in absorbance were observed after
Triton treatment, suggesting no intracellular uptake.

Cell acidification was assessed after a 24-hour incubation in Seahorse XF
unbuffered media (Agilent) containing glucose (25 mM), FBS (10%) and P/S (1%).
Media was collected after incubation and pH was measured. 4175-Luc+ cells showed
increased acidification compared to MDA-MB-231 (ratio to media control containing no
cells), seen in Figure 4.7.A. Glucose consumption and lactate production were also
evaluated in both cell lines, showing no significant differences, Figure 4.7.B & C.
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Figure 4.6 Intracellular uptake of NFbD in vitro. A. Fluorescence microscopy performed
with 4175-Luc+ cells (1.0 x 104 cells/well) treated with NFbD showed no intracellular uptake
(45 minute-incubation, 3 µM). B. Absorbance of 4175-Luc+ cells (1.0 x 104 cells/well)
before and after triton treatment showed no difference in absorbance, suggesting no uptake.
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Figure 4.7 Evaluation of cell acidification, glucose consumption and lactate production. A. pH
determination of MDA-MB-231 and 4175-Luc+ cell lines (1.0 x 106 cells/well) plotted as the ratio
to control (media) shows decreased pH for 4175-Luc+ cells after a 24-hour incubation (P-value <
0.05, unpaired t-test). B & C. Glucose consumption and lactate production of MDA-MB-231 and
4175-Luc+ cell lines show no significant difference (P-value > 0.05, unpaired t-test).
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Since glucose consumption and lactate production did not yield significant
differences between cell lines, the use of LDH inhibitors was explored to obtain a more
robust alkalization model. Two LDHis were studied, shown in Figure 4.8.A. 4175-Luc+
cells (1.0 x 104 cells/well) were treated with varying concentrations of each inhibitor,
showing no changes in cell viability, Figure 4.8.B. 4175-Luc+ cells (3.0 x 105 cells/well)
were treated with 50 µM of each LDHi and media was collected at different time points
to analyze glucose consumption and lactate production, which did not yield significant
differences Figure 4.8.C-F.
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Rai et al. J. Med. Chem. 2017, 60, 91849204
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Figure 4.8 In vitro evaluation of LDHi in 4175-Luc+ cells. A. Molecular structures of LDHi:
Compound 5 and GSK 2837808A. B. Cell viability plotted as a function of concentration evaluated
for each LDHi using Cell Titer Glo assay. C-E. Glucose consumption and lactate production plotted
as a function of time for each LDHi and media control. F. Comparison of lactate production for each
LDHi and the media control showed no significant differences (P-value >0.05, unpaired t-test).
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4.4 Discussion
This chapter describes the in vitro characterization of NFbD. Cerenkov imaging
showed the ability to detect pH changes intermolecularly and intramolecularly through
SBQ and CRET of NFbD. This detection was visualized as increasingly dark wells with
increasing pH, corresponding to absorption or SBQ at 600 nm (max SBQ). At 700 nm,
the previously dark wells become bright, corresponding to pH-dependent CRET.
Cerenkov signals obtained at different wavelengths can be used to construct a Cerenkov
spectrum for NFbD, as seen in Figure 4.1. The Cerenkov spectra presented are
normalized either to signals obtained at 840 nm or at 600 nm. Since the goal of this
project is to use NFbD for in vivo imaging of the TME, normalizing to 840 nm is of
interest, due to the increased tissue penetration of light at this wavelength. Normalizing
to the maximum SBQ value at 600 nm greatly amplifies the pH-dependent CRET signal,
aiding in visualization.

Intramolecular Cerenkov emissions exhibit identical pH-dependent SBQ and
CRET patterns but with decreased CRET. Although the reason for this needs further
exploration, we propose a potential mechanism. It is possible that NFbD and 68Ga have
more fluorescence-inducing interactions when they are mixed than when they are part of
the same molecule (chelated). Excited molecules undergo vibrational relaxation with a
higher probability than fluorescence (Jaffe and Miller, 1966). If NFbD and 68Ga are
available to interact more freely without a determined molecular arrangement (such as
with chelation), 68Ga might be able to excite more NFbD molecules, increasing the
probability of fluorescence. Another possibility could relate to the specific activity of
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68

Ga (4.1 x 107 Ci/g) (Applications, 2022). Stoichiometric calculations for a 1:1 ratio of

68

Ga to NFbD for 100 µCi of 68Ga, yields 0.036 pmoles of NFbD, equating to 3.6 x 10-4

µM in 100 µl in a 96-well plate. This is an extremely low amount of fluorophore, and it is
unlikely that it will be detected by optical imaging methods. As seen in Figure 4.4, CRET
is proportional to fluorophore concentration up to the concentration where quenching
occurs. Because of this, it is necessary to have an excess of fluorophore, which could
decrease through the chelation process, reducing CRET.

pH titration curves were constructed with inter- and intramolecular Cerenkov
imaging signals, with normalization to the 840 nm and 600 nm filters. An important
observation about these titration curves is that normalizations to signals from different
filters yield different results, leading to variation in the calculated pKa results.
Additionally, experimental conditions such as slight differences in available 68Ga activity
could affect final signal, as could the phenomena described in the previous paragraph.
These are limitations, which we believe could be further optimized to obtain consistent
values. Nonetheless, pH-dependent SBQ and CRET patterns were identical for inter and
intramolecular Cerenkov imaging, regardless of normalization, which allowed us to move
forward.

In vitro studies were performed using triple negative breast cancer cell lines
MDA-MB-231 and its metastatic variant 4175-Luc+. These cell lines were chosen as our
model because they show differential expression of LDHA, which catalyzes the
conversion from pyruvate to lactate, whose co-secretion with a proton decreases TME
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pH. 4175-Luc+ cells have increased LDHA expression, compared to MDA-MB-231.
Thus, we hypothesized that they would exhibit increased acidity in vitro and in vivo.

NFbD showed no cell toxicity and no intracellular uptake. These were considered
positive observations for in vivo imaging, since we are interested in measuring a
metabolic by-product excreted by cells into the extracellular milieu. To better understand
acidification patterns for both cell lines, media pH was measured after incubation with
each cell line. Media from 4175-Luc+ cells was significantly more acidic than media
from MDA-MB-231s after a 24-hr incubation period. This result was promising, but
when measuring glucose consumption and lactate production for each cell line there were
no significant differences. This led us to explore other viable options for modeling pH
changes that could be applied in vivo.

LDH inhibitors, Compound 5 (Rai et al., 2017) and GSK 2837808A were tested
in 4175-Luc+ cells, showing no changes in cell viability nor significant changes in lactate
production. We expected these LDHi to show significant decrease in lactate production,
since they work by inhibiting lactate dehydrogenases, but this was not the case. It is
possible that our chosen cell line was not sensitive to the effects of LDHi. Over
expression of LDHA/B could have played a role. It is also possible that increased
acidification of 4175-Luc+ cell media has contributions from other mechanisms, such as
overexpression of carbonic anhydrase or Na+-H+ exchanger (Contreras-Baeza et al.,
2019; Pavlova and Thompson, 2016; Webb et al., 2011).

58

4.5 Conclusion
Cerenkov SBQ and CRET were observed in vitro intermolecularly and
intramolecularly with NFbD in a pH-dependent manner, allowing for construction of
Cerenkov pH titration curves. In vitro experiments with NFbD using triple negative
breast cancer cell lines MDA-MB-231 and 4175-Luc+ showed no toxicity. Cell
acidification studies showed a significant decrease in pH from 4175-Luc+ media after 24hour incubation, compared to MDA-MB-231 but there was no significant difference in
glucose consumption or lactate production. Treatment with LDHi also did not alter
glucose consumption or lactate production. Although in vitro pH modulation proved
challenging, we were able to demonstrate that NFbD-Ga was sensitive to pH changes and
was a promising candidate for in vivo testing.
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Chapter 5
NFbD In Vivo

5.1 Introduction
Tumor acidity has been linked to poor prognosis on disease progression, including
increased invasion, metastasis, and chemotherapeutic resistance (Wojtkowiak et al.,
2011). Decreased pH in the TME provides an optimum environment for matrix
metalloproteinases and cathepsins, enzymes that degrade the extracellular matrix,
facilitating invasion and metastasis of cancer cells to other sites of the body (Wojtkowiak
et al., 2011). Additionally, chemotherapeutics with basic pKas can become ionized in an
acidic extracellular milieu, contributing to chemotherapeutic resistance. Charged
molecules are unable to passively cross the cell membrane, preventing them from
reaching their intended intracellular target (Wojtkowiak et al., 2011). Pre-clinical
assessment of tumor pH could provide insight on tumor status and offer an improved
approach for a priori chemotherapeutic selection.

Cerenkov imaging has been used clinically to track radiotracers such as 131I, 18FFDG and 68Ga-PSMA and explored pre-clinically in combination with fluorophores,
quantum dots and nanoparticles to visualize tumors and their metabolic activity (Pratt et
al., 2021). pH detection using Cerenkov imaging is a novel application, studied
previously in our lab with fluorinated naphthofluoresceins (Arroyo et al., 2019) and
phenol- and sulfon-phthaleins (Czupryna et al., 2015). These studies were successful, but
a more energetic Cerenkov emitter was of interest, in order to obtain a brighter and more
60

easily distinguishable pH-dependent signal. 68Ga has an endpoint energy of 1,899 keV,
which is higher than 18F (688 keV), becoming our Cerenkov emitter of choice
(Ciarrocchi and Belcari, 2017).

NFbD-Ga is a molecular construct able to provide itself with the energy needed to
absorb and fluoresce, without the need for an external excitation source. Similar
molecular constructs have also been studied by the Decréau group to assess CRET
(Bernhard et al., 2014). The coupling of a fluorophore with a Cerenkov emitter transfers
blue-weighted photons into longer wavelengths, which are less attenuated by tissue, ideal
for in vivo applications (Thorek et al., 2013). CRET, also known as Secondary Cerenkov
Induced Fluorescence Imaging (SCIFI), has been shown to have a signal to background
ratio 5.7 times greater than that of fluorescence techniques (Pratt et al., 2021). NFbD-Ga
promotes this energetic transfer in a pH-dependent manner, providing relevant
information on tumor status.

5.2 Results
In vivo PET scans were done in a tumor bearing mouse injected intravenously
with NFbD-Ga (~130 µCi) to assess probe biodistribution (Figure 5.1). NFbD-Ga did not
accumulate in the tumor (red oval in Figure 5.1.A), and was observed primarily in the
liver, bladder and GI tract. This mouse died around minute 105, which likely caused the
sudden increase in signal from the bladder observed in Figure 5.1.B. Lack of tumor
accumulation led us to continue using intratumoral injections of NFbD-Ga.
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Figure 5.1. PET-Scan of tumor bearing mouse after intravenous injection of NFbD-Ga. A.
PET scans of a tumor-bearing mouse after intravenous injection of NFbD-Ga (~130 µCi).
Tumor marked as red oval. B. Biodistribution of NFbD-Ga as a function of time shows limited
accumulation of NFbD-Ga in tumor.

Since pH determination using Cerenkov imaging depends on the pH-dependent
absorption and fluorescence of NFbD, detection of SBQ and CRET in vivo was
necessary. In vivo Cerenkov imaging was done after intratumoral injections of radioactive
NFbD-Ga (~100 µCi) in athymic nude mice bearing 4175-Luc+ or MDA-MB-231 tumor
xenografts. Figure 5.2.A is a representative Cerenkov image of 4175-Luc+ tumor bearing
mice, showing SBQ and CRET at 600 and 700 nm respectively. These phenomena can be
visualized with the naked eye. The image on the right, corresponding to CRET shows an
increase in brightness in each of the tumors, compared to their corresponding tumors on
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the left, which have a more attenuated signal (SBQ). These changes in signal are
quantified in Figure 5.2.B.
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Theoretical Cerenkov Signal
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Figure 5.2. SBQ and CRET are observed in vivo with NFbD Cerenkov imaging. Athymic nude
mice bearing 4175-Luc+ or MDA-MB-231 tumors were injected intratumorally with ~100µCi
NFbD-Ga. A. Representative Cerenkov image of 417-Luc+ tumor bearing mice showing in vivo SBQ
at 580 nm (left) and in vivo CRET at 700 nm (right). B. Average radiance signal normalized to 840
nm showing measured SBQ and CRET in vivo for 4175-Luc+ tumor bearing mice (blue bar) and
MDA-MB-231 tumor bearing mice (red bar). Theoretical Cerenkov signal was calculated as I=1/λ2,
normalized to 840 nm (green bar). Unpaired t-test SBQ P-value > 0.05 and CRET P-value > 0.05.

In addition to detecting SBQ and CRET, Figure 5.2.B shows a direct Cerenkov
imaging comparison of MDA-MB-231 and 4175-Luc+ cell lines. As discussed
previously, these cell lines were expected to show differentiable acidification patterns,
making them potential in vivo models for pH. Quantification and comparison of both
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SBQ and CRET however, does not show significant differences between the cell lines.
An interesting observation is that, even though the differences in signal are not
significant, MDA-MB-231 shows a slightly higher SBQ signal and slightly less CRET.
Considering our fluorophore, an increased SBQ signal would mean that there is less
absorption by the basic form of the molecule, and therefore a lower pH. If there is less
absorption, there will be less fluorescence, observed as reduced CRET. Since our
proposed cell line model comparison was not as robust as expected, future experiments
were performed only on 4175-Luc+ tumor xenografts.

To determine the ability of NFbD-Ga to accurately provide pH measurements, the
probe was injected intratumorally (~40 µCi) into 4175-Luc+ tumor bearing mice and
imaged using Cerenkov imaging (Figure 5.3.A). As seen above, SBQ and CRET were
once again observed in vivo, and Cerenkov pH values were obtained (pHCerenkov = 6.9 ±
0.2) by interpolation from in vitro NFbD Cerenkov pH titration curves, using CRET
ratios previously described by Piwnica-Worms (Dothager et al., 2010). CRET ratios
(Equation 5.1) are obtained by subtracting a quotient corresponding to the Cerenkov
signal within a spectral window (i.e., CRET/SBQ), with no fluorophore present, from a
quotient corresponding to Cerenkov signal within the same spectral window, in the
presence of a fluorophore (Bernhard et al., 2017; Dothager et al., 2010).

Cerenkov+Fluorophore

Cerenkov

CRET700 nm= Cerenkov+Fluorophore700 nm - Cerenkov700 nm
600 nm

Equation 5.1

600 nm
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where Cerenkov+Fluorophore700 nm corresponds to the CRET signal in the presence of
NFbD, Cerenkov+Fluorophore600 nm corresponds to SBQ signal in the presence of NFbD,
and only Cerenkov corresponds to Cerenkov signal without NFbD present.

The pH values obtained from these tumors through Cerenkov imaging were
validated against a well-established method for pH determination, 31P-Magnetic
Resonance Spectroscopy (MRS). pH values obtained from 31P-MRS, were comparable to
pH values obtained through Cerenkov imaging (pH31-P MRS = 6.92 ± 0.04), as seen in
Figure 5.3.C. The spectra from which 31P-MRS pH values were obtained are shown in
Figure 5.3.D-H, where the chemical shift of 3-APP is referenced to the α-NTP resonances
(depicted by blue arrows).
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Figure 5.3. Validation of Cerenkov pH measurements by 31P Magnetic Resonance Spectroscopy.
A. Cerenkov images of SBQ (left) and CRET (right) of nude mice bearing 4175-Luc+ tumors
injected intratumorally with ~40 µCi of NFbD-Ga. B. Average radiance signal normalized to 840
nm showing measured SBQ and CRET in vivo. C. pH values measured through Cerenkov imaging
(pH = 6.9 ± 0.2) and validated with 31P-MRS (pH = 6.92 ± 0.04). D-H. 31P-MRS spectra for each
mouse in A and its corresponding pH value.
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To determine if Cerenkov imaging can detect pH changes in vivo, animal models
for the modulation of pH were investigated. Athymic nude mice bearing 4175-Luc+
tumors were injected both intratumorally and in the muscle of the hind limb with NFbDGa (~35 µCi). The hypothesis of this experiment was to compare, in the same mouse, the
acidic environment of the tumor to that of the muscle, which should present physiological
pH of 7.4 (Jo et al., 2017). Cerenkov pH values measured for the tumor (pH = 7.3 ± 0.5)
were similar to the pH values measured for muscle (pH = 7.2 ± 0.2) for these mice,

Muscle
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6.8446

7.0

7.1753

7.5

Tumor

7.0380

8.0

7.4283

B

pH

A

7.7808

indicating that additional approaches to pH modulation may be required.

6.5
Mouse 1

Mouse 2

Mouse 3

Figure 5.4. In vivo Cerenkov imaging of 4175-Luc+ tumors with muscle as an internal control.
A. Cerenkov images of athymic nude mice bearing 4175-Luc+ tumors on the right shoulder,
injected with ~35 µCi NFbD-Ga intratumorally and in the hind muscle (Images are shown using
580 nm, 600 nm, 620 nm, 680 nm, 700 nm, 720 nm, 840 nm emission filters). B. pH values
measured through Cerenkov imaging for muscle (pH= 7.2 ± 0.2) and tumor (pH= 7. 3 ± 0.5), for
each mouse in A.
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In the next model for in vivo pH modulation (Zhao et al., 2021), athymic nude
mice bearing 4175-Luc+ tumors were injected intratumorally with NFbD-Ga (~23 µCi)
and imaged with Cerenkov imaging before and after intratumoral injections of
bicarbonate (Figure 5.5.A). The pH values calculated for each tumor before bicarbonate
injections (pH = 6.9 ± 0.3), are shown in Figure 5.5.B. The CRET ratio obtained from
Mouse 3 before bicarbonate injections was low and did not fit the Cerenkov pH titration
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Figure 5.5. In vivo pH modulation with intratumoral injections of sodium bicarbonate. A. In vivo
Cerenkov imaging of 4175-Luc+ tumor-bearing mice after intratumoral injection of naphthofluorescein
(0.11 mM) and 68Ga (~23 µCi), showing SBQ and CRET. B. Calculated Cerenkov pH values for each
tumor (pH = 6.9 ± 0.3). C. In vivo Cerenkov imaging of mice in A after intratumoral injection of 10 µL
sodium bicarbonate (200 mM). D. Calculated Cerenkov pH values for each tumor in C, (pH = 7.6 ± 0.4).
E. In vivo Cerenkov imaging of mice in A and B, after intratumoral injection of 50 µL sodium
bicarbonate (200 mM). F. Calculated Cerenkov pH values for each tumor in E, (pH = 7.6 ± 0.4).
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curve. Each tumor was then injected intratumorally with 10 µL 200 mM sodium
bicarbonate to increase pH locally, and imaged again Figure 5.5.C (Zhao et al., 2021).
After bicarbonate injection, tumor pH values increased to pH= 7.6 ± 0.4 (Figure 5.5D).
An additional 50 µL of bicarbonate was injected in an effort to push the system further
but pH was not affected (Figure 5.5.E &F).

5.3 Discussion
This chapter describes the in vivo characterization of NFbD-Ga in athymic nude
mice bearing triple negative breast cancer xenografts. First, PET imaging was performed
to assess probe biodistribution. NFbD-Ga was observed in the liver, GI tract and bladder
after intravenous injection. NFbD-Ga could be considered a large molecule, given its
molecular weight, so hepatic clearance is reasonable. NFbD-Ga, however, had minimal
tumor accumulation. Because of this, subsequent in vivo imaging experiments were
conducted with intratumoral injections. In the future, NFbD targeting should be further
explored to achieve higher probe accumulation in tumor after intravenous injections, to
provide a more translatable approach.

For in vivo translation, SBQ and CRET must be detected in mice with Cerenkov
imaging after injection with NFbD-Ga. Both SBQ and CRET were observed in athymic
nude mice bearing 4175-Luc+ or MDA-MB-231 tumors. These changes in signal
confirmed the detection of NFbD in vivo, particularly due to the presence of CRET.
NFbD absorption occurs near the wavelength at which tissue absorbs, making SBQ
subject to tissue absorption effects. On the other hand, Cerenkov-induced fluorescence is
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solely due to the presence of a fluorophore. CRET is also an important phenomenon for
in vivo pH-detection because it produces a bathochromic shift, allowing signal detection
at wavelengths that are farther away from tissue absorption (Dothager et al., 2010).
As discussed in the previous chapter, the comparison between MDA-MB-231 and
4175-Luc+ tumors was intended to serve as an acidification model where 4175-Luc+
tumors exhibited increased acidification, compared to MDA-MB-231. Cerenkov imaging
was done for both xenograft models after injection with NFbD-Ga and although the graph
in Figure 5.2.B shows a slight difference in SBQ and CRET within the models, these
were not significant. Since NFbD absorbs and fluoresces when it is in its basic or
unprotonated form, our expected results were a significantly decreased SBQ signal in
MDA-MB-231 tumors, and increased CRET, compared to 4175-Luc+ tumors. As
clarification, increased attenuation by the basic form of the fluorophore is observed as a
decrease in the signal labeled as SBQ. The photons that are being absorbed by the
fluorophore will not be detected in the signal output.

To validate our Cerenkov pH values, athymic nude mice bearing 4175-Luc+
tumors were imaged using Cerenkov after NFbD-Ga injection. Cerenkov signals
obtained, were used to interpolate Cerenkov pH values with previously described
equation for CRET ratios, proposed by Piwnica-Worms (Dothager et al., 2010). The
calculated pH values in the 4175-Luc+ tumors were 6.9 ± 0.2, which are within the
expected tumor pH range (Estrella et al., 2013). 31P-MRS was then performed on the
same mice, yielding pH values of 6.92 ± 0.04. These were promising results since the pH
values were comparable. Cerenkov pH values showed increased variation, compared to
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31

P-MRS pH values. This could be due to the inherent resolution of the technique or to

variations in intratumoral probe injection.

Muscle and tumor Cerenkov imaging was done to assess the technique’s ability to
detect pH changes in acidic tumor pH and the physiological pH in muscle. Muscle
exhibited Cerenkov pH values of 7.2 ± 0.2, while tumors exhibited pH values of 7. 3 ±
0.5. These pH values were reasonable, but muscle pH was lower than expected. In an
effort to obtain a robust pH response, tumors were injected intratumorally with sodium
bicarbonate, to increase pH. Cerenkov pH values before bicarbonate injection were pH =
6.9 ± 0.3, and pH = 7.6 ± 0.4 after bicarbonate injections, showing a 0.7 pH increase.
This change in pH can even be observed in the Cerenkov images in Figure 5.5.C as very
bright CRET in the tumors.

5.4 Conclusion

These results demonstrate that Cerenkov imaging can detect pH changes in vivo,
but highlight the limitations of the technique, which might not be sensitive enough to
detect the discreet changes in pH expected in biological systems. Since the pH
calculations are performed using ratios of CRET to SBQ, tissue absorption may affect the
final results, especially at lower wavelengths. It is important to note that these studies
provide proof of principle evidence for the potential of the technique, and additional finetuning could render this a powerful pre-clinical tool.
Chapter 6
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In vitro Phantoms
6.1 Introduction
Cerenkov imaging in vivo poses a challenge due to Cerenkov radiation having its
maximum intensity in the blue range of the spectrum, with intensity proportional to the
inverse square of the wavelength, 1/λ2 (Demers et al., 2013). This spectral region is
where tissue absorption and scattering occur, resulting in signal loss (Demers et al., 2013;
Upputuri and Pramanik, 2019). One way to enhance in vivo signal is to transfer photons
from these shorter, blue-weighted wavelengths to longer wavelengths, where tissue is
more permeable to light. This red shift of photons can be done with fluorophores,
nanoparticles, and quantum dots (Bernhard et al., 2017; Pratt et al., 2021; Thorek et al.,
2014b). This approach has proven successful, but it has been observed that tissue can still
cause Cerenkov signal attenuation in the presence or absence of these agents. Additional
information regarding tissue effects would aid in understanding differential signal
detection, particularly in agents such as NFbD, which report on tumor microenvironment.

Mathematical models for effective attenuation coefficients have been published
(Habte et al., 2018). These calculations are helpful to understand how tissue absorption
and scattering affect Cerenkov imaging, but these models were developed for direct
comparison between PET and Cerenkov imaging. Their calculations do not consider a
Cerenkov modulator, such as a fluorophore, which is the focus of this project. NFbD
absorbs at 600 nm, which is in an area of the visible spectrum that is subject to signal
attenuation due to tissue scattering and absorption. In order to obtain accurate pH
measurements, signal contributions coming from tissue and NFbD should be properly
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identified, to prevent over or underestimations of pH-dependent effects, which would
ultimately affect the final readout.
To elucidate tissue effects directly affecting NFbD in vivo and the subsequent pH
measurements obtained after Cerenkov imaging, several tissue phantoms were assessed.
These phantoms included Intralipid and India ink, which represent tissue scattering and
absorption media, respectively (Spinelli et al., 2014), bologna (Habte et al., 2018) and
chicken (Carpenter et al., 2014; Spinelli and Boschi, 2015; Spinelli et al., 2011).
Cerenkov spectra from these phantoms were evaluated, particularly at the wavelengths
were SBQ and CRET occur.

6.2 Results
Phantom studies were conducted to elucidate the effects of tissue absorption and
scattering on Cerenkov imaging with NFbD-Ga. Figure 6.1 shows a homogeneous
phantom study using intralipid (Di Ninni et al., 2011) and India ink (Di Ninni et al.,
2010), as scattering and absorption agents, respectively (Spinelli et al., 2014), with
naphthofluorescein and 68Ga, at basic pH. Increasing concentrations of intralipid seem to
have an amplification effect for Cerenkov signal, 3% intralipid exhibiting the highest
signal (Figure 6.1.A). Interestingly, SBQ and CRET were not observed. India ink, shown
in Figure 6.1.B, shows a lower Cerenkov signal than intralipid, with a typical 1/λ2
Cerenkov spectrum. SBQ and CRET were not observed. Similar spectra were observed
when India ink was mixed with intralipid and for the naphthofluorescein control (Figure
6.1.C). Naphthofluorescein concentration might have been too low to exhibit SBQ and
CRET for this experiment.
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Figure 6.1. Intralipid and India Ink homogeneous phantom. Cerenkov imaging
spectrum showing average radiance as a function of wavelength, for various
concentrations of A.intralipid. B. India Ink. C. intralipid and India Ink. D.
naphthofluorescein control. A-D contain 45.8 µM naphthofluorescein, ~30 µCi/well of
68
Ga, pH>8, for each well, except control.

To further address the effects of tissue absorption and scattering for Cerenkov
imaging of tumor pH, tissue phantom studies were conducted. Figure 6.2 shows a tissue
phantom using bologna of different thicknesses to cover wells containing Cerenkov
emitters. Bologna was chosen due to the apparent homogeneity of this tissue. Figure
6.2.A and 6.2.B show Cerenkov images at 600 nm, 680 nm, 700 nm, and 840 nm for a
well plate containing 240 µM naphthofluorescein and 68Ga (~38 µCi) at pH>8 (left
columns) and 68Ga (~38 µCi) at pH>8 (right columns) with and without tissue. Figures
6.2 C-D show Cerenkov spectra corresponding to each of these conditions.
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In Figure 6.2.C, a typical 1/λ2 Cerenkov spectrum is observed for the 68Ga
control. Figure 6.2.D shows the Cerenkov spectrum with naphthofluorescein present,
exhibiting SBQ and CRET. In Figures 6.2.E and F, we observe Cerenkov spectra without
and with naphthofluorescein, respectively. Both spectra show similar intensities, with an
attenuation followed by an increase in signal at 2.5 mm and 3 mm, even when no
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naphthofluorescein is present, suggesting tissue absorption and scattering. Signal
obtained from 6 mm tissue is highly attenuated.
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Figure 6.2. Effects of Bologna tissue on Cerenkov emission. A-B. Cerenkov images for a
96-well plate with and without bologna at 600 nm, 680 nm, 700 nm, and 840 nm.
Cerenkov imaging spectrum showing average radiance as a function of wavelength for C.
~38 µCi/well of 68Ga (pH>8). D. 240 µM naphthofluorescein and ~38 µCi/well of 68Ga
(pH>8). E. ~38 µCi/well of 68Ga (pH>8), and 2.5 mm, 3 mm, or 6 mm bologna slices. F.
240 µM naphthofluorescein, ~38 µCi/well of 68Ga (pH>8), and 2.5 mm, 3 mm, or 6 mm
bologna slices.
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In an effort to visualize tissue effects on a more relevant model, tumor tissue and
skin tissue from tumor bearing mice were evaluated with Cerenkov imaging in a phantom
model (Figure 6.3). Figure 6.3.A shows a Cerenkov image at varying wavelengths of a
well-plate prepared with 240 µM naphthofluorescein and ~36 µCi 68Ga at pH 4, 7.4 and
9.5. Naphthofluorescein was not present in the 68Ga control. As seen in Figure 6.3.B,
wells from Cerenkov imaging in Figure 6.3.A showed SBQ and CRET at pH 9.5 when
taken as a ratio to 840 nm (green bars). Figure 6.3.C shows the plate in Figure 6.3.A with
tissue slices over the wells, measuring ~2 mm in thickness. Tumor heterogeneity is
detected as brighter spots in the same well covered with tissue. SBQ and CRET are not
observed (Figure 6.3.D). In Figure 6.3.E, the same plate is covered with mouse skin,
measuring ~1 mm in thickness. Less heterogeneity is observed, but no SBQ or CRET are
present (Figure 6.3.E).
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Figure 6.3. Phantom with mouse tumor tissue and skin tissue. A. Well plate
68
prepared with 240 µM naphthofluorescein and 36 µCi Ga, at pH 4, 7.4 and 9.5. B.
Cerenkov signal at SBQ and CRET for A, for each condition. C. Well-plate in A,
with tumor tissue (~2 mm thick) over wells. D. Cerenkov signal at SBQ and CRET
for B. E. Well-plate in A, with skin tissue (~1 mm) over wells. F. Cerenkov signal at
SBQ and CRET for E. B, D & F are presented as ratios to 840 nm.

Since SBQ and CRET were not observed through skin in Figure 6.3, an
experiment was conducted to determine whether skin attenuates Cerenkov signal and to
what extent. In Figure 6.4, athymic nude mice bearing 4175-Luc+ tumor xenografts were
injected intratumorally with NFbD-Ga (~27 µCi). These mice were imaged using
Cerenkov imaging (Figure 6.4.A), and then euthanized. Skin over the tumors was
removed (Figure 6.4.C), and the tumors were then excised (Figure 6.4.E) and halved
(Figure 6.4.G). After each step, Cerenkov imaging was performed, and SBQ and CRET
signals were plotted. In Figure 6.4.B, SBQ and CRET were observed for each mouse
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after intratumoral injection of NFbD-Ga. Similarly, in Figure 6.4.D, SBQ and CRET
were also observed, after skin removal, suggesting that SBQ and CRET can indeed be
seen through skin. Tumor excision did not seem to increase SBQ and CRET detection,
which could be due to a decrease in activity (Figure 6.4.F & H).

Because of the apparent SBQ and CRET observed in the bologna phantoms,
results presented in Figure 6.4 required further investigation, which led us to our final
tissue phantom using raw frozen chicken breast. Figure 6.5.A and B show Cerenkov
images of a well plate prepared with 240 µM naphthofluorescein and ~22 µCi 68Ga at
various pH values, with or without chicken tissue. Chicken tissue was chosen because of
increased tissue uniformity, in terms of heterogeneity and thickness. SBQ and CRET
were observed with no chicken tissue at pH 9.5, in Figure 6.5.C (green bars). When
chicken tissue was added (1 mm), SBQ and CRET were still observed at pH 9.5. This
effect is also observed with 2 mm of tissue (Figure 6.5.E). Tissue effects begin to obscure
SBQ and CRET at 3 mm (Figure 6.5.F).

This chicken phantom provided useful additional information. In the absence on
naphthofluorescein, 1 mm of tissue attenuated 64% of the Cerenkov signal. With the
addition of naphthofluorescein, signal is further attenuated to 17%. In the absence of
tissue, naphthofluorescein attenuated 82% of the signal, solely corresponding to SBQ.
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there was also a 10% increase in Cerenkov signal due to CRET. For this technique, the
depth penetration is 3 mm.
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Figure 6.4. In vivo SBQ and CRET observed through skin. A. Cerenkov images of athymic nude
mice bearing 4175-Luc+ tumors injected intratumorally with NFbD-Ga (~27 µCi). B.
Quantification of SBQ and CRET spectra from these images. C. Cerenkov images of exposed
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imaging of excised tumors. F. Quantification of SBQ and CRET. G. Cerenkov images of tumors in
E, sliced in half, with SBQ and CRET quantified in H.
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Figure 6.5. Effects of chicken breast tissue phantom on Cerenkov emissions. A. Cerenkov
68
images of well plate prepared with 240 µM naphthofluorescein and ~22 µCi Ga, at pH 4, 7.4 and
9.5 at SBQ (600 nm, left) and CRET (700 nm, right). B. Representative Cerenkov images of the
well plate with a 1 mm chicken slice at SBQ (left) and CRET (right). C. Cerenkov signal at SBQ
and CRET of conditions in A. D. Cerenkov signal at SBQ and CRET of conditions in A, with a ~1
mm slice of chicken. E. Quantification of Cerenkov signal at SBQ and CRET of conditions in A,
with a ~2 mm slice of chicken. F. Cerenkov signal at SBQ and CRET of conditions in A, with a ~3
mm slice of chicken. G. Percent of tissue attenuation signal as a function of tissue thickness (no
naphthofluorescein). H. Percent signal from naphthofluorescein relative to gallium control as a
function of tissue thickness.
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6.3 Discussion
This chapter evaluated tissue phantoms applied to our proposed technique of pH
determination by Cerenkov imaging. Intralipid and India ink have been previously used
to simulate tissue scattering and absorption (Alexander et al., 2021; Axelsson et al., 2011;
Demers et al., 2013; Spinelli et al., 2014; Tendler et al., 2020). The homogeneous
phantom presented in Figure 6.1, as Cerenkov spectra of average radiance as a function
of wavelength showed an amplification of Cerenkov signal as Intralipid concentration
increased. We believe this is due to an increase in refractive index, which has a linear
relationship with intralipid concentration (Ding et al., 2005). The Frank-Tamm equation
shows that Cerenkov intensity is proportional to refractive index, exhibiting a higher
intensity within a medium with increasing refractive index (Ciarrocchi and Belcari, 2017;
Mitchell et al., 2011). These spectra, however, did not exhibit SBQ or CRET, which is
probably due to the low concentration of naphthofluorescein, confirmed by the absence
of SBQ and CRET in the naphthofluorescein control. Since homogenous phantoms of
Intralipid and India ink did not accurately reflect the effects of tissue, we abandoned this
model system and switched to tissue phantoms.

It is important to note that this chapter mainly includes data obtained with
naphthofluorescein mixed with 68Ga. The reason for this is twofold. First, by the end of
the experiments, the activity available from the 68Ga generator had decreased to a point
where the volume needed to obtain the required activity was very high (See Appendix).
Second, imaging with the widely available naphthofluorescein parent compound was
more economical compared to using the NFbD probe. Here the assumption was made that
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intermolecular imaging with naphthofluorescein behaved identically to NFbD, given that
it is the parent fluorophore of our probe, and that we demonstrated that the optical
properties were maintained after conjugation.

The goal of using tissue phantoms was to understand how tissue effects affect
SBQ and CRET, and to be able to separate the signal modulations of NFbD from that
arising from tissue. In Figure 6.2, a bologna tissue phantom was presented, in which a
well plate containing naphthofluorescein and 68Ga at basic pH was imaged using
Cerenkov with and without bologna slices of various thicknesses (2.5 mm, 3 mm and 6
mm) placed on top. A similar model was used by Habte et al. (2018). Without tissue, the
Cerenkov spectra behaved as expected, with a typical 1/λ2 Cerenkov dependence when
there was no naphthofluorescein present and with SBQ and CRET observed in the
presence of naphthofluorescein. In the presence of bologna however, Cerenkov spectra
exhibited similar characteristics with and without naphthofluorescein. Signal was
attenuated at 600 nm, which is the wavelength where maximum SBQ occurs for
naphthofluorescein. Tissue absorption also occurs at 600 nm (Upputuri and Pramanik,
2019). At 700 nm, where CRET occurs, there is an increase in signal, compared to 600
nm. Since this is observed in the presence and absence of naphthofluorescein, we can
conclude that observed changes arise mostly from tissue effects. If tissue did not absorb
near 600 nm, Figure 6.2.E would likely look similar to Figure 6.2.C. As expected, the
Cerenkov signal decreased with increasing tissue thickness.
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Since bologna was too opaque to be able to see SBQ and CRET from
naphthofluorescein, a more realistic model of mouse tumor and skin tissue were studied
(Figure 6.3). SBQ and CRET were observed at pH 9.5 from wells containing
naphthofluorescein and 68Ga and no tissue. SBQ and CRET were not observed with
tumor tissue or skin, which could be due to both tissue effects and low 68Ga activity. With
this phantom, tumor heterogeneity was evident in the Cerenkov images. In Figure 6.3.C
there are tumor areas in the same well that show increased brightness, corresponding to
more transparent tumor tissue within the tissue slice.

To better understand the effects of skin. NFbD-Ga (~27 µCi) was injected
intratumorally into tumor bearing mice and imaged using Cerenkov imaging. The mice
were then euthanized., the skin over the tumor removed and Cerenkov imaging was
performed again. Apparent SBQ and CRET were observed through skin and without skin,
SBQ and CRET were not observed in excised tumor, even when sliced in two, although
the signal did increase markedly.

The chicken phantom in Figure 6.5 provided important information regarding
contributions of naphthofluorescein to SBQ and CRET. A plate was prepared with
naphthofluorescein and 68Ga, at various pH values and 1 mm slices of chicken breast
tissue were placed over the wells and imaged, up to 3 mm tissue, where signal began to
attenuate. SBQ and CRET were observed for 1 mm and 2 mm of tissue, suggesting the
maximum depth penetration of this technique to be 3 mm. In addition to this,
contributions of tissue attenuation to SBQ were determined. 64% of signal was attenuated
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with 1 mm of tissue with no naphthofluorescein. When naphthofluorescein is added, there
is a further attenuation to 17%. Impressively, when there was no tissue present,
naphthofluorescein attenuated 82% of the signal. This phantom was analyzed using a
25% threshold per ROI in Living Image, because of low activity.

This chapter highlighted some factors to consider when applying this technique.
Cerenkov imaging with NFbD should be directed to superficial applications, given the
depth penetration of 3 mm, where tissue begins to obscure measurable signal. Achieving
CRET is of utmost importance for detection of NFbD, due to its absorption wavelength
being subject to tissue effects. Loss of activity plays a critical role in signal detection and
differentiation, as well as probe concentration, both of which were discussed in Chapter
4. Based on these caveats, this technique may need additional optimization in order to be
described as quantitative.

6.4 Conclusion
This chapter provides examples of various phantoms to assess tissue effects
playing a role in SBQ and CRET detection for this project. An appropriate phantom
model was developed using chicken breast. With this phantom, higher tissue uniformity
was achieved, which allowed the depth penetration of the technique to be determined.
Additionally, the contribution from tissue and naphthofluorescein to signal attenuation
was assessed and determined.
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Chapter 7
Conclusions and Future Directions
7.1 Introduction
This chapter will summarize the main takeaways and conclusions of the work
presented in this thesis and provide a framework that describes the future directions of
this project.

7.2 Conclusion Summary and Significance
The work presented in this thesis focused on the development, characterization
and application of NFbD-Ga, a pH sensitive imaging probe, designed to report on TME
acidity in vivo. Our approach toward this goal was systematic and each step built upon
the previous one.

NFbD was successfully conjugated and chelated to 68Ga. NFbD was shown to
maintain the pH sensitivity and optical properties of its parent compound 5(6)carboxynaphthofluorescein, which was vital to perform Cerenkov imaging and pH
determination in vivo. NFbD coupling with 68Ga as a Cerenkov emitter proved to provide
pH-dependent selective bandwidth quenching (SBQ) and subsequent Cerenkov radiation
energy transfer (CRET). This coupling was achieved intermolecularly, with 68Ga mixed
with NFbD, and intramolecularly, with NFbD chelated with 68Ga.
Three relevant observations were obtained from these experiments. Firstly,
intermolecular and intramolecular Cerenkov imaging exhibited different intensities, but
identical pH dependent SBQ and CRET patterns. Intermolecular Cerenkov imaging
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presented a higher signal than intramolecular Cerenkov imaging. Second, Cerenkov pKa
for intermolecular and intramolecular imaging were lower than the ones obtained through
optical spectroscopy. This has been previously observed by Czupryna et al. and Arroyo et
al. (Arroyo et al., 2019; Czupryna et al., 2015). The reason for this phenomenon is yet to
be determined. Lastly, we observed that data normalization to 600 nm, which is the
wavelength at which SBQ occurs for our probe, showed increased CRET, aiding in data
visualization.

For in vivo pH determination, Cerenkov imaging was performed on athymic nude
mice bearing triple negative breast cancer 4175-Luc+ tumors and average signal values
obtained were used to interpolate pH values from in vitro pH titration curves. These pH
values were ultimately calculated as CRET Ratios, described by Piwnica-Worms and his
group (Dothager et al., 2010). Experimental pH values obtained from Cerenkov imaging
were validated against 31P-MRS. Data interpretation was faced with the challenge of
tissue effects, which we aimed to elucidate through phantoms. Our proposed chicken
tissue phantom (Carpenter et al., 2014; Spinelli and Boschi, 2011; Spinelli et al., 2011)
provided valuable insight into the individual contributions of tissue and
naphthofluorescein to attenuation. These studies provided insight into an application of
Cerenkov imaging that could benefit from optimization, growth, and development.

This thesis aims to introduce a novel application to Cerenkov imaging, which
provides functional information on the tumor microenvironment, offering an alternative
for the pre-clinical assessment of acidity. As mentioned previously, acidity in the TME is
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linked to invasion and metastasis and resistance to chemotherapeutics. Magnetic
Resonance Imaging (MRI) techniques have been studied for measurement of TME
acidity, such as chemical exchange saturation transfer (CEST) (Anemone et al., 2021;
Chen and Pagel, 2015; Tang et al., 2020). Optical imaging approaches, however, are
generally less expensive and provide high sensitivity (Peñate Medina et al., 2021).

7.3 Future Directions

This work can be described as proof-of-principle studies for the development of a
novel application of Cerenkov imaging, namely using this technique to report on TME
pH. Significant strides were achieved towards this goal, but further optimization should

Signal
Enhancement

Targeting

NFbD-Ga

Fluorophore
Optimization

pH Modulation
Models

Figure 7.1. Summary scheme for NFbD-Ga Optimization. NFbD-Ga and its
applications could be optimized by exploring targeting, signal enhancement
and additional or modified fluorophores. This model could be explored more
accurately with optimized pH modulation models.
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be explored to obtain more sensitive and accurate pH measurements. Figure 7.1 provides
a global summary of what we believe this optimization should entail.
Since NFbD-Ga has minimal tumor absorption, targeting alternatives should be
explored to optimize delivery. The synthesis for an updated molecular scaffold for
NFbD-Ga was developed by Dr. Anatoliy Popov. This scaffold consists of a trisubstituted
aminotriazine, to which 5(6)-carboxynaphthofluorescein, DOTA and a targeting moiety
can be linked, as seen in Figure 7.2. A moiety such as an RGD peptide, which is the main
binding domain of several extracellular matrix proteins like fibronectin and fibrinogen
and can bind to multiple types of integrins (Bellis, 2011), can be considered for active
targeting (Agnello et al., 2021; Chadar et al., 2021; Hwang et al., 2020; Kutova et al.,
2019; Mamnoon et al., 2021).

Figure 7.2. Proposed Structure for NFbD Targeting Scaffold. Trisubstituted aminotriazine capable of
linking a fluorophore, a targeting moiety and a chelator.

The molecular construct in Figure 7.2 provides the flexibility to incorporate
alternate fluorophores, chelators and targeting moieties, according to the desired target.
This adds an avenue to consider additional pH-sensitive fluorophores that could enhance
our in vivo Cerenkov pH measurements by presenting optical properties better suited to
our proposed application. 5(6)-Carboxynaphthofluorescein was able to detect pH
changes, but its pKa is relatively high, making tumor pH measurements (pH =6.5-6.9)
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challenging (Estrella et al., 2013). A fluorophore like SNARF-5F (λabs/ex= 573 nm/631
nm, EC 49,000 M-1cm-1, pKa = 7.2), has a better pKa for pH measurements of the TME,
although its absorption and emission wavelengths are less optimal. We have previously
observed CRET with SNARF-1 (λabs/ex= 576 nm/635 nm, EC 48,000 M-1cm-1), which has
similar optical properties as SNARF-5F, suggesting the feasibility of this approach
(Figure 7.3) (ThermoFisher, 2022a, b).
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Figure 7.3. SNARF-1 Cerenkov Radiation Energy Transfer. Shaded region corresponds
to CRET.

As mentioned previously, since Cerenkov radiation is blue-weighted, it exhibits
higher intensities at shorter wavelengths. Incorporating a fluorophore with a large Stokes
shift into our molecular construct could have the potential to transfer more photons to an
area of the spectrum with enhanced tissue penetration. Such an example is presented by
Jan Grimm and his group, through the use of dual-labeled nanoparticles with quantum
dots and 89Zr (Zhao et al., 2017). Although pH sensitivity could be a challenge, there
have been reports of pH-sensitive quantum dots, providing a viable alternative (Manon et
al., 2020; Tomasulo et al., 2006).
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Signal enhancement of Cerenkov radiation could also be done by increasing the
refractive index of the injection solution of NFbD-Ga. Cerenkov signal is proportional to
the refractive index of the medium, so it is theoretically possible to modulate the intensity
of the signal through adjusting the refractive index. Elucidating the optimal solution for
injection, considering solvents such as saline and dextrose, could be of benefit.
Additionally, Cerenkov signal can be enhanced by substituting the radioemitter 68Ga to
90

Y, which has a higher endpoint energy (2280 keV) and a half-life of 64.1 hours. Using
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Y would allow experimental procedures with extended time-points and provide a higher

intensity signal.

To better understand the capabilities of NFbD-Ga to detect pH changes in vivo,
additional pH modulation models should be elucidated. These models could include the
genetic knockout of glycolytic enzymes such as LDHA using CRISPR/Cas9 to induce an
alkalization effect. It has been reported that lactate secretion is not significantly affected
through the knockout of either LDHA or LDHB. Both must be knocked out to see an
effect (Ždralević et al., 2018). These knockouts did not affect in vivo tumor growth,
which could allow for in vivo pH measurements. Pharmacological approaches for
inhibiting LDH (Rai et al., 2017) or MCTs (Benjamin et al., 2018; Contreras-Baeza et al.,
2019) could also be further explored.

7.4 Final Thoughts
With this thesis, we hope to introduce a novel application of Cerenkov imaging
that could provide therapeutic benefit to oncologic patients. The field of Cerenkov
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imaging has been developing greatly throughout the last decade. With each new
discovery and application, this field demonstrates its amazing breadth and potential.
Talented researchers around the world are working towards translating Cerenkov to the
clinic, with clinical trials (ClinicalTrials.gov Identifier: NCT03484884) and developing
imaging devices for the operating room (Ciarrocchi et al., 2021; Olde Heuvel et al., 2020;
Olde Heuvel et al., 2019). These are exciting strides, that will take Cerenkov from bench
to bedside.
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Appendix

A.1. Regions of Interest (ROI)
Data analysis and processing is quintessential for any kind of quantitative
imaging technique, including pH determination by Cerenkov imaging. Our standard
processing workflow schemes are shown in Figure A.1. The Cerenkov imaging data was
collected on an IVIS Spectrum and processed using the LivingImage Software from
PerkinElmer. Representative images obtained on the IVIS Spectrum are shown on the left
of Figure A.1, where all the mice are observed in a single image. This distance to the
camera will depend on the field of view (FOV) settings determined before imaging. A
larger FOV is used to take advantage of the high throughput capability of the IVIS,
imaging 5 mice at once. Using LivingImage, regions of interest (ROIs) were drawn on
the white light image of the tumor, followed by measurement of the Cerenkov emission
within that region at different wavelengths. We found that this method led to variable
results for the same ROIs in the same studies (Figure A.1.A). Test-retest reproducibility,
a method for evaluating a tool’s reliability to obtain reproducible results (Balagurunathan
et al., 2014; Vaz et al., 2013) showed an average 10.8 ± 5.03 variability when the same
tumor was measured multiple (3) times. A way to mitigate these variable results was to
zoom in on the region where the ROIs were to be drawn, to minimize the detection and
quantification of random pixels near the desired area. In addition, zooming in increases
ROI uniformity, which is harder to distinguish with the “regular” or zoomed-out image.
In Figure A.1.B, ROIs were drawn on a zoomed-in image, where only one tumor could
be seen in the window, which decreased the test-retest reproducibility percent difference
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to 3.58 ± 1.98. At lower magnifications, the researcher conducting the analysis could
observe distinct and uniform ROIs, but the software detects some differences affected the
final ROI measurement. Zooming in to the desired area allows for better construction of
ROIs, so the software can measure with higher accuracy.

A

Imaging

Data Collection

B

Data Processing

Test-Retest
Reproducibility

Imaging

Data Collection

Data Processing

Test-Retest
Reproducibility

Figure A.1. ROI Test-Retest Reproducibility. A. Image analysis scheme after Cerenkov
imaging, with ROIs drawn on image obtained from the IVIS Spectrum. B. Image analysis
scheme after Cerenkov imaging, with ROIs drawn on zoomed in image, focusing on tumor.
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A.2. Data Normalization
Cerenkov imaging is multispectral and continuous and can be detected through
various filters in the visible region, allowing for the construction of Cerenkov spectra.
When NFbD is added, the Cerenkov spectra become pH dependent. Obtaining Cerenkov
signals from different filters allows for signal normalization to relevant wavelengths, as
seen in Figure A.2. For this project, we identified 3 filters of particular importance: 600
nm, 680 nm, and 840 nm. When the signal is normalized to 600 nm, it is normalized to
SBQ. This normalization amplifies pH dependent CRET, aiding in visualization (Figure
A.2.B). This normalization also corresponds to the first term in the CRET Ratio equation
(Dothager et al., 2010), seen below.

CRET700 nm=

Cerenkov+Fluorophore700 nm Cerenkov700 nm
Cerenkov+Fluorophore600 nm Cerenkov600 nm

The isosbestic point for NFbD is 680 nm, which is why it is considered a relevant filter
for normalization, since it is the point where the measurements are pH independent (Jo et
al., 2017). Finally, normalization to 840 nm has been done in our previous Cerenkov
studies (Arroyo, 2019; Arroyo et al., 2019), which is the longest wavelength measured,
outside of the range of fluorescence and where the maximum tissue penetration of light
occurs.

Normalization to each of these wavelengths produces changes in Cerenkov
spectra that affect the fit of the pH titration curves, which are used to interpolate pH
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values. Figure A.2.E-H show representative pH titration curves of NFbD (~74 µCi)
normalized to each of the aforementioned wavelengths. The figure legends include the
pKa value, obtained from GraphpadPRISM as the LogIC50 after “Sigmoidal, 4PL, X is
log(concentration)” analysis, and the corresponding R2 value (goodness of fit), which was
highest at 600 nm normalization.

As previously mentioned, pH determination in vivo was done using CRET Ratio
calculations, as proposed by Piwnica-Worms, which can potentially correct for tissue
effects by subtracting independent Cerenkov signal at SBQ and CRET wavelengths. pH
titration curve constructed with CRET Ratios is presented in Figure A.2.I, which shows
similar pKa and R2 values to 600 nm normalization.
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Figure A.2. Cerenkov spectra and pH titration curves. A-D. Cerenkov spectra of
average radiance signal as a function of wavelength (NFbD ~74 µCi). A. Average
radiance signal presented without normalization. B-D. normalized to 600 nm, 680 nm,
and 840 nm, respectively. E-H. Corresponding Cerenkov pH titration curves for A-D. I.
Cerenkov pH titration curve calculated using the CRET Ratio equation. Some error bars
are smaller than the data points.
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A.3. Cerenkov imaging of 68Ga in mice
Imaging of 68Ga was done with mice bearing 4175-Luc+ tumor xenografts,
immediately after euthanasia. 68Ga (~40 µCi) was injected intratumorally in each mouse
and in vivo Cerenkov spectra were obtained (Figure A.3). These data were used as an
average for the in vivo Cerenkov signal with no NFbD, to calculate CRET ratios in vivo,
using the Piwnica-Worms method (Dothager et al., 2010).

In Figure A.3 these data are presented as average radiance with no normalization
(Figure A.3.A), normalized to 600 nm filter (Figure A.3.b), normalized to 680 nm filter
(isosbestic point) (Jo et al., 2017) in Figure A.3.d and normalized to 840 nm (Figure
A.3.e). In each of these normalizations, Mice 1 and 4 have decreased signal at 600 nm
and show a signal increase at 680 nm, while Mice 2 and 3 do not exhibit this signal
difference. This is an important observation, particularly because we have observed
similar signal patterns previously in bologna phantoms (Chapter 6). Additionally,
Cerenkov imaging at 580 nm show that Mice 2 and 3 have the brightest tumors. Since
these tumors were injected with the same activity of 68Ga, it is possible that these changes
in signal correspond to depth of injection. A shallower injection would result in less
tissue attenuation effects. This was evaluated with the tissue phantoms in Chapter 6,
where it was shown that this technique was optimal for superficial applications, given its
low depth penetration. Differences in depth of injection provided valuable information,
but this variation could be overcome with stereotactic injection systems.
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Figure A.3. Mice imaging of 68Ga. A. Cerenkov images of euthanized mice bearing 4175-Luc+
tumor xenografts, after ~40 µCi injection of 68Ga. B-E. Cerenkov spectra for each mouse in A,
presented as average radiance as a function of wavelength, normalized to signal obtained at 600
nm filter, 680 nm filter and 840 nm filter or no normalization.

99

A.4 68Ga Generator
Throughout this project, the activity obtained from the 68Ga generator
exponentially decreased, affecting the number, nature and type of experiments that could
be performed. This was challenging, not only because of the decrease in activity but also
because of the nature of our Cerenkov emitter, 68Ga, which has a half-life of 68 minutes.
This short half-life made it difficult to perform long experiments and to combine other
nuclear modalities such as PET scans, prior to or following Cerenkov imaging. In Figure
A.4, we present a graph plotting activity obtained from rinsing the generator as a function
of time. The red bar represents the period of COVID shutdowns, where experiments were
paused. This decrease in activity meant that many post shutdown experiments had to be
performed using direct injections of 68Ga and naphthofluorescein, rather than NFbD-68Ga.
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Figure A.4. Activity decrease from 68Ga generator. Activity obtained
from generator rinse as a function of time shows exponential decrease in
activity.
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A.5 Nuclear Magnetic Resonance (NMR)
NMR was done in combination with MALDI-TOF for probe characterization on a
Bruker DMX 500. 10 mg of NFbD were dissolved in 600 µL of deuterated water
buffered to pH 14 using NaOD. NFbD exhibited aromatic signals, consistent with
naphthofluorescein, within the previously observed range of 6.34 ppm - 8.37 ppm
(Arroyo et al., 2019). The assignment of these signals, based on our previous publication,
is (δ, ppm): 8.35-8.15 (m, 2H, H8 + H6), 7.82-7.30 (m, 2H, H4’+H5’+H6’+H7’), 7.10-692, m, 2H, H2+H12), 6.71-6.22 (m, 5H, H7’+H5+H9+H4+H10).

Aliphatic signals were also observed, corresponding to DOTA (3.3 ppm) and the
aliphatic linker (1.2 ppm – 1.4 ppm). This area contains signals of solvents and reagents
(3.15 -methanol, 3.23 and 0.98 -ethanol, 2.31 and 0.81 triethylamine and 2.45acetonitrile). Numerous conformations of DOTA (Aime et al., 1997; Csajbók et al., 2004;
Kubíček et al., 2010) in NFbD broaden the signals, producing overlapping peaks. A
broad multiplet 3.1-2.9, 6H corresponds to NCH2CO2-. Broad multiplets 2.85-2.2 and
2.19-1.7, 14H are resonances of C(O)NCH2 and NCH2CH2N; and broad mutiplets 1.531.0, 4H correspond to C(O)NHCH2CH2CH2CH2NHC(O) (Audras et al., 2017).
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Figure A.5. 1H-NMR spectrum of NFbD (500 MHz, pH 14, D2O). NFbD has numerous conformations
resulting in overlapping signals in the spectrum. Aromatic signals from naphthofluorescein were consistent
with the range previously observed (6.34 - 8.37 ppm) (Arroyo et al., 2019). Aliphatic protons were
observed between 1.2 and 3.3 ppm with the signals at 3.3 ppm and from 1.2 to 1.4 ppm assigned to the
amino acetic acids of DOTA and the central hydrogens of the aliphatic linker respectively.
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A.6 Ex Vivo Protein Immunoblot
LDHA/LDHB expression had been evaluated in vitro with metastatic triple
negative breast cancer cell lines MDA-MB-231 and 4175-Luc+. Results showed
increased LDHA expression in 4175-Luc+ cell lines, compared to MDA-MB-231 cell
lines (Arroyo, 2019). To assess LDHA and LDHB expression in tumors, protein
immunoblots (commonly known as Western blots) were performed ex vivo. MDA-MB231 and 4175-Luc+ tumor xenografts were excised from athymic nude mice. These
tumors were then homogenized and lysed to perform protein immunoblotting. LDHA and
LDHB expression was evaluated against β-tubulin, a housekeeping protein (Figure A.6).

Data suggested that there were no consistent expression patterns of LDHA or
LDHB for MDA-MB-231 or 4175-Luc+ tumors, which could be due to tumor xenograft
heterogeneity. Although these tumors are expected to develop in a similar fashion, it is
likely that they are distinguishable, even when corresponding to the same cell line,
particularly because they are injected in individual mice (1 tumor/mouse). Additionally,
the tumor microenvironment adds a layer of complexity that is not present in vitro, which
could relate to in vitro LDHA and LDHB expression patterns not translating in vivo
(Boix-Montesinos et al., 2021). It is also relevant to note that these studies presented
some challenges in terms of antibody binding and noise, and future studies should focus
on immunohistochemical staining for evaluating expression of these proteins.
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Figure A.6. Protein Immunoblot for LDHA and LDHB ex vivo. Protein immunoblots compared to βtubulin for 4 tumors, 2 corresponded to MDA-MB-231 xenografts and 2 corresponded to 4175-Luc+
xenografts, samples were loaded in duplicate. A. LDHA immunoblot evaluated against β-tubulin. No
observable differences between cell lines are detected. B. LDHB immunoblot evaluated against βtubulin. No observable differences between cell lines are detected.
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